Wednesday – Sunday, November 14-18, 2012

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Daniel G. Clair, MD

Sponsored by
Cleveland Clinic

www.VEITHsymposium.org
ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:
CONTENTS

Acknowledgments.......................... Inside Front Cover
General Information...................................................... 7
Accreditation............................................................... 9
Faculty Disclosure......................................................... 9
Social Events............................................................... 10
Hotel and Travel........................................................ 10
Agenda................................................................. 11–71
Faculty Listing......................................................... 73–80
Registration.......................................................... 81–82
Save the Date......................................................... Inside Back Cover
17th European Vascular Course
March 10-12, 2013
Maastricht, The Netherlands
www.vascular-course.com

1250 participants
84 invited lectures
42 company presentations
2 high quality textbooks
Vascular International Masterclass
Vascular Access Masterclass
European Venous Masterclass
Interactive Case Discussions
Hands-on courses, EVC e-Learning

Learning by training
Emerging Management Options for Pulmonary Embolism

COURSE LEADER
Michael R. Jaff, DO

Endovenous Management of Varicose Veins

COURSE LEADERS
Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

Hemodialysis Access

COURSE LEADERS
Larry A. Scher, MD
Thomas M. Vesely, MD

Management of Proximal Venous Obstruction

COURSE LEADERS
Kenneth Ouriel, MD, MBA
Peter Gloviczki, MD

WOUNDS

COURSE LEADER
Dieter O. Mayer, MD

POSTER SESSION

JUDGES
Peter Gloviczki, MD
Ali F. AbuRahma, MD
Ali Amin, MD, RVT
Enrico Ascher, MD
Giorgio M. Biasi, MD
Piergiorgio Cao, MD
Nicholas J.W. Cheshire, MD
Krassi Ivancev, MD, PhD
Christos D. Liapis, MD
Frans L. Moll, MD, PhD
Kenneth Ouriel, MD, MBA
Dieter Raithel, MD, PhD
Vicente Riangban, MD, PhD
Norman M. Rich, MD
Carlo Setacci, MD
Matt M. Thompson, MD
Eric L.G. Verhoeven, MD, PhD
SPECIAL NON-CME ACCREDITED ACTIVITY
AT VEITHsymposium

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES

Wednesday, November 14, 2012 - 5:30 P.M. – 7:45 P.M.
Trianon Ballroom, 3rd Floor
5:30 P.M.  Cocktails and Heavy Hors d’oeuvres will be served throughout the evening.

Moderators: Plinio Rossi, MD
Carlo Setacci, MD
Frank J. Veith, MD

5:45 – 5:55  Endovascular Treatment Of An 8-Week-Old Embolic Occlusion Of The Popliteal Trifurcation
Nicolas A. Diehm, MD

5:55 – 6:00  Discussion

6:00 – 6:10  Pedal Revascularization
Thomas Rand, MD

6:10 – 6:15  Discussion

6:15 – 6:25  Evolution Of The Proximal Neck And Aneurysm Rupture Post EVAR: Endovascular Options
Daniele Gasparini, MD

6:25 – 6:45  Discussion

6:45 – 6:55  Unusual Aortic Reinterventions
Robert A. Morgan, MD

6:55 – 7:00  Discussion

7:00 – 7:10  How To Survive A Potential Catastrophic Complication During EVAR
Fabrizio Fanelli, MD

7:10 – 7:15  Discussion

7:15 – 7:25  Iatrogenic Arterial Ruptures During Endovascular Procedures
Andrej Schmidt, MD

7:25 – 7:30  Discussion

7:30 – 7:45  Panel Discussion

7:45  Adjourn
NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Wednesday, the symposium offers over 750 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Provide information about the latest technologies, techniques and data from clinical trials for endovascular repair of AAAs and thoracic and abdominal aortic disease
- Provide information about the latest data, techniques and technologies for carotid disease management
- Provide information about the latest developments in pharmacologic agents for the management of vascular disease
- Provide information on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease
- Provide new information about the treatment of venous disease
- Provide new information about the latest developments in hemodialysis access
- Provide information about new developments in wound care
- Provide updated information about the medical or non-interventional management of vascular disease

GENERAL INFORMATION
GENERAL INFORMATION

TARGET AUDIENCE
Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists and all others interested in the management of vascular disease.

TRANSLATION LANGUAGES
We will have translation from English to Spanish, Portuguese, Russian and Mandarin Chinese from Thursday to Sunday.

SIXTH ANNUAL POSTER SESSION
This year, VEITHsymposium in collaboration with the International Society for Vascular Surgery (ISVS) will continue its feature designed to allow vascular surgeons who are ISVS members to present their work at the meeting. Posters selected by a distinguished panel of judges (Drs. Peter Gloviczki, Ali AbuRahma, Ali Amin, Enrico Ascher, Giorgio Biasi, Piergiorgio Cao, Nicholas Cheshire, Krassi Ivancev, Christos Liapis, Frans Moll, Kenneth Ouriel, Dieter Raithel, Vicente Riambau, Norman Rich, Carlo Setacci, Matt Thompson, and Eric Verhoeven) will be available for viewing throughout the meeting in the Rhinelander Gallery, 2nd floor. The formal Poster Session judging will be open to all interested attendees on Friday afternoon from 2:00 p.m. to 4:30 p.m. The distinguished panel of judges will select the best poster presentations for awards on the basis of the poster and 3-minute oral presentations. These awards will be presented on Saturday, November 17, 2012 in the Grand Ballroom East, 3rd floor.

GENERAL SESSIONS
General Sessions will be held in the Grand Ballroom East and West on the 3rd floor on Thursday, Friday, Saturday and Sunday.

Wednesday Component Sessions will be held as follows:

Hemodialysis Access
Location: Trianon Ballroom, 3rd floor

Emerging Management Options For Pulmonary Embolism
Location: Grand Ballroom West, 3rd floor

Management Of Proximal Venous Obstruction
Location: Grand Ballroom West, 3rd floor

Endovenous Management Of Varicose Veins
Location: Grand Ballroom East, 3rd floor

WOUNDS
Location: Gramercy Suites A&B, 2nd floor

Multidisciplinary Acute Stroke Management
Location: Murray Hill Suites A&B, 2nd floor

VIDEO SESSION FEATURING COMPLICATIONS AND UNUSUAL CASES
Wednesday, November 14, 2012 - 5:30 P.M. - 7:45 P.M.
Location: Trianon Ballroom, 3rd floor

There are some European interventionalists who are cutting edge leaders in new and better techniques for performing below knee endovascular treatments and carotid artery stenting. Some of these individuals will be included in this Wednesday evening program featuring challenging recorded live cases in these two important areas.

This program will be led by Dr. Plinio Rossi and will start at 5:30 P.M. and go until approximately 7:45 P.M., with ample time for audience discussion and questions. This program will provide a state-of-the-art update on exciting new treatment techniques. Cocktails and heavy hors d’oeuvres will be provided throughout the evening, courtesy of Cook Medical. (This is a non-CME activity.)
GENERAL INFORMATION

ACCREDITATION STATEMENT
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 52 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

CME CERTIFICATES AND COURSE EVALUATION FORMS
Your CME certificate will be available online at www.veithsymposium.org. An e-mail will be sent to all registered attendees immediately following the meeting with a unique password and instructions on how to obtain the certificate and complete a brief, optional course evaluation. Please note that the e-mail will be sent to the e-mail address that was used to register the attendee.

FACULTY DISCLOSURE
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.

ADA STATEMENT
The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to admin@veithsymposium.org, or by fax to (845) 368-2324.

ONLINE ACCESS TO ABSTRACTS
All conference attendees will receive instructions on how to access and print out available meeting abstracts prior to the meeting. These abstracts will be available on the program page of the VEITHsymposium web site at www.veithsymposium.org. Abstracts will be available on the web site for one full year.

ONLINE CONFERENCE LIBRARY
The entire program with all the talks, all the slides, all the videos - fully synchronized - and all the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please call 800-987-9314, ext. 300.
GENERAL INFORMATION

HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of $389 plus taxes per night. This rate is available until the block is filled or until October 19, 2012. Please request the VEITH rate when reserving your accommodations.

Hilton New York (Symposium Site)
1335 Avenue of the Americas
New York, NY 10019
(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)

American Express Business Travel at
The Cleveland Clinic Foundation
9500 Euclid Avenue, P83
Cleveland, OH 44195
Phone: (800) 955-6111 (U.S. toll free)
(216) 444-2564 (U.S. and International)
Fax: (216) 444-2500
E-mail: Diane.M.Geneva@aexp.com

SOCIAL EVENTS

Tickets (Theater, Opera, Symphony, Sports, Etc.)
Marilyn Rosenblatt, Charge d'Affaires
Phone: (212) 794-2773
E-mail: blattcda@aol.com

FROM HIGH ABOVE THE WORLD TO ‘HIGH’ ABOVE NEW YORK

New York was selected by NASA as the permanent home for the retired Space Shuttle Enterprise.

Join our tour and be among the first to see it at its new exhibit site on the USS Intrepid, as part of the Intrepid Sea, Air and Space Museum. After viewing other exhibits on this historic aircraft carrier, our van (with guide) will take us to the High Line, currently the city’s most popular visitor attraction. A lovely meandering elevated park affording unique, spectacular views of the city, this reclaimed railroad trestle called the High Line winds its way high above the Meat Packing District and beyond through one of New York’s most exciting neighborhoods, past hotels, new residential buildings, elegant boutiques, shops, markets and restaurants in the streets below.

Then, we'll stop for a memorable lunch at the nearby Tribeca Grill, a true New York City landmark, co-owned by renowned restauranteur Drew Nieporent and legendary actor Robert De Niro.

Cost: $125.00 (includes admission, transportation, tour guide and lunch).

To reserve space please make your check (U.S. bank only) payable to Charge d’Affaires, Inc. and mail it to Marilyn Rosenblatt, Charge d’Affaires, Inc., 75 East End Avenue, #11L, New York, NY 10028. We regret that we cannot accept payment by credit card.

For more information please call (212) 794-2773 or e-mail blattcda@aol.com.
CONCURRENT WEDNESDAY PROGRAMS

SESSIONS 1 & 2
Hemodialysis Access
7:55 A.M. – 5:00 P.M.
Trianon Ballroom, 3rd Floor

SESSION 3
Emerging Management Options For Pulmonary Embolism
10:00 A.M. – 12:00 P.M.
Grand Ballroom West, 3rd Floor

SESSION 4
Management Of Proximal Venous Obstruction
1:00 P.M. – 3:15 P.M.
Grand Ballroom West, 3rd Floor

SESSIONS 5 & 6
Endovenous Management Of Varicose Veins
8:00 A.M. – 5:15 P.M.
Grand Ballroom East, 3rd Floor

SESSIONS 7 & 8
WOUNDS
9:00 A.M. – 5:20 P.M.
Gramercy Suites A&B, 2nd Floor

SESSIONS 9 & 10
Multidisciplinary Acute Stroke Management
7:55 A.M. – 4:00 P.M.
Murray Hill Suites A&B, 2nd Floor

SESSION 1  (Trianon Ballroom, 3rd Floor)
HEMODIALYSIS ACCESS – PART 1

7:55 – 8:00
Welcome And Introduction
Larry A. Scher, MD
Thomas M. Vesely, MD

PART 1A: INTERVENTIONAL PROCEDURES FOR
HEMODIALYSIS ACCESS

Moderators: Larry A. Scher, MD
Thomas M. Vesely, MD

8:00 – 8:08
Where Is The SVC/RA Junction And Why Is It
Important In The Dialysis Patient
Jacob Cynamon, MD

8:09 – 8:17
Access Survival After Prophylactic Angioplasty
Timothy A. Pflederer, MD

8:18 – 8:26
Stent Grafts For Venous Anastomotic Stenosis
Thomas M. Vesely, MD

8:27 – 8:35
Angioplasty, Stents Or Stent Grafts For Swing-Point
Or Cephalic Arch Stenosis
Theodore F. Saad, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:36</td>
<td>Percutaneous Management Of The Non-Maturing Fistula</td>
<td>John E. Aruny, MD</td>
</tr>
<tr>
<td>8:45</td>
<td>Blood Flow Measurement During Hemodialysis Access Procedures</td>
<td>Oleg Leontiev, MD</td>
</tr>
<tr>
<td>8:54</td>
<td>Cardiovascular Implantable Device Guidelines In ESRD Patients</td>
<td>Haimanot (Monnie) Wasse, MD, MPH</td>
</tr>
<tr>
<td>9:03</td>
<td>Endovascular Treatment Of Pacemaker Related Central Venous Stenosis</td>
<td>Dheeraj Rajan, MD</td>
</tr>
<tr>
<td>9:12</td>
<td>Management Of SVC Syndrome And Complex Central Venous Stenosis</td>
<td>Richard J. Gray, MD</td>
</tr>
<tr>
<td>9:21</td>
<td>Radiofrequency Recanalization Of Central Venous Stenosis</td>
<td>Neal J. Halin, DO</td>
</tr>
<tr>
<td>9:30</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>9:50</td>
<td>Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)</td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Uncommon Complications Of Hemodialysis Catheters</td>
<td>Kenneth D. Abreo, MD</td>
</tr>
<tr>
<td>10:24</td>
<td>Inadvertent Arterial Catheterization During Central Venous Catheter Insertion</td>
<td>Tony P. Smith, MD</td>
</tr>
<tr>
<td>10:33</td>
<td>Translumbar Hemodialysis Catheters</td>
<td>Gregory J. Nadolski, MD</td>
</tr>
<tr>
<td>10:42</td>
<td>Balloon-Assisted Technique For The Placement Of The Outflow Segment Of The HeRO Device</td>
<td>Hector Ferral, MD</td>
</tr>
<tr>
<td>10:51</td>
<td>Subclavian Vein Access: Over The Wire Graft Implantation Techniques With Hybrid Graft Technology</td>
<td>Stephen Settle, MD</td>
</tr>
<tr>
<td>11:00</td>
<td>Computational Fluid Dynamics Of Hemodialysis Grafts</td>
<td>Christof Karmonik, PhD</td>
</tr>
<tr>
<td>11:09</td>
<td>Vessel-Select Access System For Percutaneous AV Fistula Creation</td>
<td>Jeffrey E. Hull, MD</td>
</tr>
<tr>
<td>11:18</td>
<td>Arteriovenous Fistula Creation Using The Optiflow Anastomotic Connector</td>
<td>Prabir Roy-Chaudhury, MD, PhD</td>
</tr>
<tr>
<td>11:27</td>
<td>Blood Flow As Predictor Of Patency For Hemodialysis Access Procedures</td>
<td>Lars Lonn, MD, PhD</td>
</tr>
<tr>
<td>11:36</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>11:55</td>
<td>Lunch Break – Americas Hall 1, 3rd Floor Visit Exhibits and Pavilions (2nd and 3rd Floors)</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>12:45</td>
<td>Genetic Causation Of Hemodialysis Access Stenosis</td>
<td>Timmy Lee, MD, MSPH</td>
</tr>
<tr>
<td>12:54</td>
<td>Mathematical Model Of Brachiocephalic Fistula: New Explanation For Success Of DRIL Procedure In Treating Hand Ischemia</td>
<td>William D. Paulson, MD</td>
</tr>
<tr>
<td>1:03</td>
<td>The Effect Of Access Blood Flow On Cardiac Function</td>
<td>Louise Moist, MD, MSc</td>
</tr>
<tr>
<td>1:21</td>
<td>Targeting Catheter Last In Fistula First</td>
<td>Joseph A. Vassalotti, MD</td>
</tr>
<tr>
<td>1:37</td>
<td>When Should Peritoneal Dialysis Be Considered?</td>
<td>Jack Work, MD</td>
</tr>
<tr>
<td>1:46</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>2:00</td>
<td>Bundling And Revaluing Hemodialysis Access Services</td>
<td>Sean P. Roddy, MD</td>
</tr>
<tr>
<td>2:09</td>
<td>Accountable Access Care Organization</td>
<td>Timothy A. Pfleiderer, MD</td>
</tr>
<tr>
<td>2:18</td>
<td>Fistula Maturation Is Related To Logistics, Communication, Training And Competency</td>
<td>Prabir Roy-Chaudhury, MD, PhD</td>
</tr>
<tr>
<td>2:27</td>
<td>Training Surgeons To Perform Vascular Access</td>
<td>Mitchell L. Henry, MD</td>
</tr>
<tr>
<td>2:36</td>
<td>Nursing Assessment And Management Of Access Related Aneurysms And Pseudoaneurysms</td>
<td>Brian LaMendola, RN, MBA</td>
</tr>
<tr>
<td>2:45</td>
<td>Surgical Management Of Access Related Aneurysms And Pseudoaneurysm</td>
<td>Gary A. Gelbfish, MD</td>
</tr>
<tr>
<td>2:54</td>
<td>Risk Of Infection After Stent Graft Placement In Hemodialysis Grafts</td>
<td>Tony P. Smith, MD</td>
</tr>
<tr>
<td>3:00</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>3:25</td>
<td>Break - Visit Exhibits and Pavilions</td>
<td>(2nd and 3rd Floors)</td>
</tr>
<tr>
<td>3:45</td>
<td>Can Early Cannulation Grafts Reduce Catheter Dependency?</td>
<td>Marc H. Glickman, MD</td>
</tr>
<tr>
<td>3:54</td>
<td>Management Of Lower Extremity Steal Syndrome</td>
<td>Eric K. Peden, MD</td>
</tr>
<tr>
<td>4:03</td>
<td>Endovascular And Surgical Options For Inflow Stenosis In Patients With Dysfunctional AV Access</td>
<td>Karl A. Illig, MD</td>
</tr>
</tbody>
</table>
### SESSION 2–4

**4:12 – 4:20** Options For Vascular Access In The Obese Patient  
*David L. Cull, MD*

**4:21 – 4:29** Use Of A Bovine Carotid Artery For Hemodialysis Access  
*Eric K. Peden, MD*

**4:30 – 4:38** Forearm Basilic Vein Transposition  
*Larry A. Scher, MD*

**4:39 – 5:00** Panel Discussion

**5:00** Adjourn

---

### SESSION 3 (Grand Ballroom West, 3rd Floor)

**EMERGING MANAGEMENT OPTIONS FOR PULMONARY EMBOLISM**

**Moderator:** Michael R. Jaff, DO

**10:00 – 10:02** Introduction To The Session  
*Frank J. Veith, MD*

**10:03 – 10:08** Welcome And Introduction Of The Topic  
*Michael R. Jaff, DO*

**10:09 – 10:18** What Must The Vascular Specialist Know About PE  
*Victor F. Tapson, MD*

**10:19 – 10:28** Intravenous rtPA For Pulmonary Embolism: Does This Work  
*Ido Weinberg, MD, MSc*

**10:29 – 10:38** Percutaneous Pharmacomechanical Intervention For PE: An Overview  
*Nils Kucher, MD*

**10:39 – 10:48** The EKOS Strategy  
*Tod C. Engelhardt, MD*

**10:49 – 10:58** The VORTEX Strategy  
*Christopher J. Kwolek, MD*

**10:59 – 11:08** Angiojet Device To Treat Massive And Submassive PEs  
*Jeffrey Y. Wang, MD*

**11:09 – 11:18** ECMO As The Bridge To Definitive Therapy For PE: Hybrid Approaches  
*Kenneth Rosenfield, MD*

**11:19 – 11:28** Less May Be More: The Use Of Catheter Directed Thrombolysis In Conjunction With IVC Filters For Massive And Submassive PE  
*Gary M. Ansel, MD*

**11:29 – 11:38** Techniques, Tips And Tricks For Endovascular Management Of Pulmonary Embolism  
*Ali Amin, MD, RVT*

**11:39 – 11:48** Interventional Management Of Occlusive Illofemoral Deep Venous Thrombosis: Another Evolution To A Revolution?  
*Mark H. Meissner, MD*

**11:49 – 12:00** Panel Discussion/Questions And Answers

**12:00** Adjourn

**12:00 – 1:00** Lunch Break – Americas Hall 1, 3rd Floor Visit Exhibits and Pavilions (2nd and 3rd Floors)

---

### SESSION 4 (Grand Ballroom West, 3rd Floor)

**MANAGEMENT OF PROXIMAL VENOUS OBSTRUCTION**

**Moderators:** Kenneth Ouriel, MD, MBA  
*Peter Gloviczki, MD*

**1:00 – 1:05** Introduction To The Session  
*Kenneth Ouriel, MD, MBA  
Frank J. Veith, MD*
DEBATE: Should Acute Isolated Femoropopliteal DVT Be Managed Aggressively

1:06 – 1:13
Yes, Remove The Thrombus With Pharmacomechanical Means
Cynthia K. Shortell, MD

1:14 – 1:21
No, Anticoagulation Alone Is Best
Thomas W. Wakefield, MD

1:22 – 1:30
Discussion And Vote

DEBATE: Venous Thoracic Outlet Syndrome: Intervention Or Observation?

1:31 – 1:38
Axillo-Subclavian Vein Thrombosis Should Be Treated With Early Thrombolysis, First Rib Resection And Open Venous Reconstruction
Robert W. Thompson, MD

1:39 – 1:46
There Is No Evidence That Intervention Is Better Than Anticoagulation For Acute Axillo-Subclavian Vein Thrombosis
Mark H. Meissner, MD

1:47 – 1:55
Discussion And Vote

DEBATE: How Should We Manage May-Thurner Syndrome?

1:56 – 2:03
May-Thurner Syndrome Should Be Treated Aggressively With Venous Stenting In All Symptomatic Patients
Seshadri Raju, MD

2:04 – 2:11
Compression Treatment Alone Is Best For May-Thurner Syndrome
Gregory L. Moneta, MD

2:12 – 2:20
Discussion And Vote

DEBATE: The Best First-Line Modality For Iliofemoral Venous Thrombus Is . . .

2:21 – 2:28
Open Surgical Thrombectomy Is The Standard
Anthony J. Comerota, MD

2:29 – 2:36
Thrombolysis With Ultrasound Is Best
Mark J. Garcia, MD

2:37 – 2:45
Discussion And Vote

DEBATE: The Nutcracker Syndrome: We Can Treat It But Should We?

2:46 – 2:53
Nutcracker Syndrome Is Best Managed By Open Surgical Reconstruction
Peter Gloviczki, MD

2:54 – 3:01
Non-Aggressive Management Of Renal And Pelvic Venous Congestion Is Best
Cees H.A. Wittens, MD, PhD

3:02 – 3:10
Discussion And Vote

3:11 – 3:15
Summary And Conclusions
Peter Gloviczki, MD
Kenneth Ouriel, MD, MBA

3:15
Adjourn

Visit Exhibits and Pavilions (2nd and 3rd Floors)
SESSION 5 (Grand Ballroom East, 3rd Floor)
ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART I

Moderators: Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

8:00 – 8:06 Welcome – Endovascular Venous Surgery At A Glance
Jose I. Almeida, MD

8:07 – 8:12 Anatomy And Nomenclature Of The Venous System
Mark A. Adelman, MD

8:13 – 8:18 Standards For Venous Mapping And Reflux Study
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

8:19 – 8:24 Clinical Evaluation Of The Venous Patient
Mark H. Meissner, MD

8:25 – 8:30 Why Treat Varicose Veins: Is There Evidence?
Apostolos K. Tassiopoulos, MD

8:31 – 8:36 How To Use CEAP And VCSS In Clinical Practice?
Michael A. Vasquez, MD, RVT

8:37 – 8:42 Step-By-Step Endovenous Thermal Ablation Of The GSV
Edward G. Mackay, MD

8:43 – 8:48 Step-By-Step Endovenous Thermal Ablation Of The SSV
Caron B. Rockman, MD

8:49 – 8:54 Step-By-Step Endovenous Chemical Ablation Of The GSV
Ted King, MD

8:55 – 9:00 It Does Not Matter Which Device For Truncal Vein Ablation, The Results Are The Same
Alun H. Davies, MA, DM

9:01 – 9:06 Modern Day Stripping Is As Good As Endovenous Thermal Ablation
Cees H.A. Wittens, MD, PhD

9:07 – 9:12 Review Of Randomized Controlled Trials Comparing Endovenous Thermal And Chemical Ablation
Bo G. Eklof, MD, PhD

9:13 – 9:18 Step-By-Step: Ambulatory Phlebectomy
Paul Pittaluga, MD

9:19 – 9:24 “Powered” Phlebectomy: Are We There Yet For Significant Branch Varicosities?
Thomas W. Wakefield, MD

9:25 – 9:30 Should Adjuvant Procedures Be Performed At The Same Time As Endovenous Thermal Ablation? Evidenced Based
Peter J. Pappas, MD

9:31 – 9:36 Guidelines (USA vs UK) In The Management Of Superficial Venous Disease
Peter Gloviczki, MD

9:37 – 9:42 Endovenous Thermal Ablation: Technical Pearls For Complex Anatomy
Jose I. Almeida, MD, RVT

Lowell S. Kabnick, MD

9:49 – 9:54 When Is Prophylaxis Needed During GSV/SSV Ablation?
Caron B. Rockman, MD

9:55 – 10:00 DEBATE: C2 Venous Disease Is Progressive: Its Treatment Should Be A Covered Insurance Benefit
Alun H. Davies, MA, DM
10:01 – 10:06
DEBATE: C2 Venous Disease Is Progressive: Its Treatment Should Not Be A Covered Insurance Benefit
Jose I. Almeida, MD, RVT

10:07 – 10:12
Hurt Locker: Complications Of Endovenous Therapy
Renate R. van den Bos, MD, PhD

10:13 – 10:18
Hurt Locker: Complications Of Foam And Liquid Sclerotherapy
Edward G. Mackay, MD

10:19 – 10:24
Hurt Locker: Steps To Avoid Endothermal Heat Induced Thrombosis
Mikel Sadek, MD

10:25 – 10:30
Hurt Locker: Steps To Avoid Saphenous And Sural Nerve Paresthesia
Jean Luc Gerard, MD

10:31 – 10:36
Hurt Locker: Steps To Avoid Lymphatic Complications After Varicose Vein Surgery
Paul Pittaluga, MD

10:37 – 10:42
Hurt Locker: Complications From The Treatment Of Klippel-Trenaunay Syndrome
Byung-Boong Lee, MD

10:43 – 10:48
How To Differentiate Venous Ulcers From Others
Raghu Kolluri, MD

10:49 – 10:54
Other Adjuncts To Heal Ulcers
William A. Marston, MD

10:55 – 11:00
Reducing Venous Ulcers By 50% In 10 Years: The Next Steps
Peter Henke, MD

11:01 – 11:06
Are We Really To Believe That Correction Of Saphenous Reflux Does Not Aid Ulcer Healing? Debunking The ESCHAR Trial
Thomas F. O’Donnell, Jr., MD

11:07 – 11:12
DEBATE: Perforator Ablation Is Overused
Steve Elias, MD

11:13 – 11:18
DEBATE: Perforator Ablation Is Not Overused
Mark S. Whiteley, MS

11:19 – 11:24
Combined Treatment With Compression Therapy And Ablation Of Incompetent Superficial And Perforating Veins Reduces Ulcer Recurrence In Patients With CEAP 5 Venous Disease
Peter F. Lawrence, MD

11:25 – 11:30
Update On Varicose Vein Recurrence: The REVATA Trial
Ronald G. Bush, MD

11:31 – 11:36
Update On Commercially Available Foam Sclerotherapy: Results Of Phase 3 FDA Trial
Lowell S. Kabnick, MD

11:37 – 12:00
Panel Discussion
Panelists:
Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD
Mark A. Adelman, MD
Michael C. Dalsing, MD
Alun H. Davies, MA, DM
Peter Gloviczki, MD
William A. Marston, MD
Thomas F. O’Donnell, Jr., MD
Thomas W. Wakefield, MD
Cees H.A. Wittens, MD, PhD

12:00 – 1:00
Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)
SESSION 6  (Grand Ballroom East, 3rd Floor)
ENDOVENOUS MANAGEMENT OF VARICOSE VEINS – PART 2
Moderators: Jose I. Almeida, MD, RVT
Lowell S. Kabnick, MD

1:00 – 1:05  Compression Therapy For Lymphatic Disease Treatment: Is That All There Is?
Raghu Kolluri, MD

1:06 – 1:11  Compression: Should We Use Post Saphenous Ablation? Evidence?
Todd Berland, MD

1:12 – 1:17  Compression: Medical Necessity Requirement Prior To Treatment: Really? Evidence?
Glenn Jacobowitz, MD

1:18 – 1:23  Compression: Should We Use During Sports: Evidence?
Steve Elias, MD

1:24 – 1:29  Introduction Of IACVC: Accreditation Of Vein Centers
John Blebea, MD, MBA

1:30 – 1:35  If I Were To Build & Credential The “Ideal Vein Doctor” I Would Add These Ingredients…
Michael C. Dalsing, MD

1:36 – 1:41  Misperceptions Of The American Board of Phlebology
Anthony J. Comerota, MD

1:42 – 1:47  Update: Cyanoacrylate For GSV Ablation
Jose I. Almeida, MD, RVT

1:48 – 1:53  Update: Mechanochemical GSV Ablation
Steve Elias, MD

1:54 – 1:59  Should Endovenous Ablation Of Small Diameter Great Saphenous Veins Be Performed On Patients With Symptomatic Varicose Veins?
Alan M. Dietzek, MD, RPVI

2:00 – 2:05  Update: Steam Ablation For GSV Ablation
Renate R. van den Bos, MD, PhD

2:06 – 2:11  Can Venous Ablation Be Performed In Patients With A History Of Ipsilateral DVT?
Lowell S. Kabnick, MD

2:12 – 2:17  Where Will We Be In 2015?
Lowell S. Kabnick, MD

2:18 – 2:23  Present And Future Of Chronic Cerebrospinal Venous Insufficiency (CCVSI): Is This A Real Syndrome?
Mark H. Meissner, MD

2:24 – 2:29  CCSVI: Our Results And Should We Continue To Treat?
Marzia Lugli, MD

2:30 – 2:35  The Next Breakthrough In Venous Research
Joseph D. Raffetto, MD

2:36 – 2:41  Is Venous Disease Arterial?
Seshadri Raju, MD

2:42 – 2:47  Implications Of Expanded Venous Reflux Study
Thomas W. Wakefield, MD

2:48 – 2:53  Detecting Iliac, IVC, Ovarian Vessels By Duplex Ultrasound
Judy M. Holdstock, DMU, DCR

2:54 – 2:59  Pelvic Reflux With Or Without Pelvic Symptoms (C2 Or Higher): Should We Treat And How?
Mark S. Whiteley, MS

3:00 – 3:05  Best Imaging Techniques For Deep Venous Evaluation
Barry Stein, MD

Robert B. McLafferty, MD
3:12 – 3:17 Proposed Classification System For Iliocaval Occlusion
William A. Marston, MD

3:18 – 3:23 Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not?
Enrico Ascher, MD

3:24 – 3:29 My Approach To Iliac Vein Outflow Occlusive Disease
Jose I. Almeida, MD, RVT

3:30 – 3:35 Endovascular Treatment Of Chronic Venous Obstruction: Tips And Tricks Including Complete Obstruction
Mark J. Garcia, MD

3:36 – 3:41 DEBATE: We Should Treat Intramuscular Calf Vein DVT With Standard Anticoagulation
Joann Lohr, MD

3:42 – 3:47 DEBATE: We Should Not Treat Intramuscular Calf Vein DVT With Standard Anticoagulation
Clifford M. Sales, MD, MBA

3:48 – 3:53 Superficial Venous Thrombophlebitis: To Treat Or Not To Treat?
Joseph D. Raffetto, MD

Anthony J. Comerota, MD

4:00 – 4:05 Importance Of A Venous Registry And Opportunities In The Vascular Quality Initiative (SVS)
Jack L. Cronenwett, MD

4:06 – 4:11 What Drugs Should We Be Using For DVT Treatment?
Russell H. Samson, MD, RVT

4:12 – 4:17 Timing And Patient Selection For Thrombolysis
Antonios P. Gasparis, MD

4:18 – 4:23 Should We Use The D-Dimer Test And/OR Residual Thrombus To Manage DVT?
Timothy K. Liem, MD

4:24 – 4:29 Association Of Deep Vein Reflux And Obstruction In PTS: Which Is The Culprit?
Seshadri Raju, MD

4:30 – 4:35 Is There Any Treatment Available For Patients Who Already Have PTS?
Jose I. Almeida, MD, RVT

4:36 – 4:41 Mechanism Of Venous Valve Closure And The Role Of The Valve In Circulation
Fedor Lurie, MD, PhD

4:42 – 4:47 Deep Venous Valvular Reconstruction: Indications, How And Results
Marzia Lugli, MD

4:48 – 4:53 Natural History Of Advanced CVI (CEAP 4-6) Following Endovenous Ablation
Jennifer A. Heller, MD

4:54 – 5:15 Panel Discussion
Panelists: Jose I. Almeida, MD, RVT
Enrico Ascher, MD
Lowell S. Kabnick, MD
Anthony J. Comerota, MD
Jack L. Cronenwett, MD
Alan M. Dietzek, MD, RPVI
Antonios P. Gasparis, MD
Marzia Lugli, MD
William A. Marston, MD
Mark H. Meissner, MD
Mark S. Whiteley, MS

5:15 Adjourn
SESSION 7  (Gramercy Suites A&B, 2nd Floor)
WOUNDS – PART 1

9:00 – 9:10 Opening Remarks
Dieter O. Mayer, MD

PART 1A: NEW CONCEPTS IN WOUND CARE
Moderator: Giacomo Clerici, MD

9:10 – 9:20 Utility Of V.A.C.® Therapy For Split-Thickness Skin Grafting
Bauer E. Sumpio, MD, PhD

9:20 – 9:30 Discussion

9:30 – 9:40 Topical Oxygen; Breathing New Life Into Chronic Wounds
Giacomo Clerici, MD

9:40 – 9:50 Discussion

9:50 – 10:00 Diagnosis And Management Of Atypical Wounds Of The Lower Leg: An Update
Marco Romanelli, MD, PhD

10:00 – 10:10 Discussion

10:10 – 10:20 A Systematic Approach To Surgical Debridement
Dieter O. Mayer, MD

10:20 – 10:30 Discussion

10:30 – 11:00 Break – Visit Exhibits and Pavilions
(2nd and 3rd Floors)

PART 1B: FREE PAPER SESSION
Moderator: Dieter O. Mayer, MD

11:00 – 11:07 Critical Limb Ischemia:  Endovascular Below-The-Knee Maximal Revascularization Increases Wound Healing
Nirvana Sadaghianloo, MD

11:07 – 11:12 Discussion

11:12 – 11:19 Maggot Therapy For Chronic Ulcer:  Systematic Review, Meta-analysis And Cost-Effective
Chumphon Wilasrusmee, MD, MSc

11:19 – 11:24 Discussion

11:24 – 11:31 A Novel Robotic Monofilament Test For Diabetic Neuropathy
Chumphon Wilasrusmee, MD, MSc

11:31 – 11:36 Discussion

11:36 – 11:43 Can Audible Doppler Signal Be Used As An Alternative To Ankle Brachial Pressure Index
Afshaneh Alavi, MD

11:43 – 11:48 Discussion

11:48 – 11:55 How Frequently Does A Malignant Wound Present As Leg Ulcer?
Afshaneh Alavi, MD

11:55 – 12:00 Discussion

12:00 – 12:30 Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 8  (Gramercy Suites A&B, 2nd Floor)
WOUNDS – PART 2

PART 2A: EVIDENCE BASED MEDICINE IN WOUND CARE
Moderator: Bauer E. Sumpio, MD, PhD

12:30 – 12:40 How To Implement EBM In Our Wound Clinic Or Surgical Department
Hester Vermeulen, PhD
SESSION 8

12:40 – 12:50
Delphi Studies In Wound Care Research: A New Better Tool For EBM?
Anne M. Eskes, RN, MSc

12:50 – 1:00
How To Treat Donor Site Wounds: An Evidence Based Approach
Fleur E. Brölmann, MD

1:00 – 1:20
Panel Discussion

1:20 – 1:30
The Association Of Ulceration Of The Foot With Cardiovascular And All-Cause Mortality In Patients With Diabetes: A Meta-analysis
Robert J. Hinchliffe, MD

1:30 – 1:40
Evidence Based Update: Diabetic Foot Ulcers And The Wound Bed Preparation Model
R. Gary Sibbald, MD

1:40 – 1:50
Panel Discussion

PART 2B: CONCEPTS FOR THE DIABETIC FOOT
Moderators: Giacomo Clerici, MD
Marc A. Brenner, DPM

1:50 – 2:10
Facts That Every Vascular Surgeon Needs To Know About The Diabetic Foot
Michael E. Edmonds, MD

2:10 – 2:20
Discussion

2:20 – 2:40
Foot Deformities In The Diabetic - More Than Charcot Foot
Thomas Boeni, MD

2:40 – 2:50
Discussion

2:50 – 3:00
A New Device For Topical Intermittent Rapid Oxygenation – Compression To Increase Hyperoxygenated Blood Flow To The Horrendous Septic Diabetic Foot
Magdiel Trinidad-Vasquez, MD

3:00 – 3:10
Discussion

3:10 – 3:20
Achilles Tendon Complete Tenotomy: THE Solution For Treating Neuropathic Diabetes Mellitus Foot Ulcers?
Wayne Caputo, DPM

3:20 – 3:30
Discussion

3:30 – 3:50
Break – Visit Exhibits and Pavilions
(2nd and 3rd Floors)

PART 2C: VASCULAR INTERVENTIONS IN WOUND CARE
Moderator: Joseph L. Mills, MD

3:50 – 4:00
Peripheral VORTEC Procedures: Who Really Profits And Who Maybe Does Not?
Gabriel Szendro, MD

4:00 – 4:10
Discussion

4:10 – 4:20
Provide Me An Inflow And I Will Heal Your Foot
Marc A. Brenner, DPM

4:20 – 4:30
Discussion

4:30 – 4:40
Below-The-Knee Stent Or Balloon In Severe Critical Limb Ischemia With Extensive Wounds: Is It Worth The Effort?
Sebastian E. Debus, MD, PhD

4:40 – 4:50
Discussion

4:50 – 5:00
Is Tibial Angioplasty Effective To Improve Wound Healing In Patients With End-Stage Renal Disease (ESRD)?
Werner Lang, MD

5:00 – 5:10
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:10</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Dieter O. Mayer, MD</td>
</tr>
<tr>
<td>5:20</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>

**SESSION 9** *(Murray Hill Suites A&B, 2nd Floor)*

**MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT – PART I**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:55</td>
<td>Welcome And Introduction</td>
</tr>
<tr>
<td></td>
<td>Allan L. Brook, MD</td>
</tr>
</tbody>
</table>

**PART 1A: THE BASICS OF STROKE - INCLUDING THE EPIDEMIOLOGY AND NATURAL HISTORY**

**Moderators:** Allan L. Brook, MD Joshua A. Hirsch, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Stroke: Where We Have Been And Now The 21st Century And Things To Look Forward To</td>
</tr>
<tr>
<td></td>
<td>Lou Caplan, MD</td>
</tr>
<tr>
<td>8:08</td>
<td>TIAs - What Is New: Diagnosis And When To Treat Aggressively</td>
</tr>
<tr>
<td></td>
<td>David S. Liebeskind, MD</td>
</tr>
<tr>
<td>8:17</td>
<td>Brain Blood Flow - Physiology And Understanding</td>
</tr>
<tr>
<td></td>
<td>Colin P. Derdeyn, MD</td>
</tr>
<tr>
<td>8:35</td>
<td>The Clinical Exam: Quick Pearls That Tell You: Large Or Small Vessel Occlusion</td>
</tr>
<tr>
<td></td>
<td>Daniel L. Labovitz, MD</td>
</tr>
<tr>
<td>8:48</td>
<td>Door To Revascularization Time: Optimization And Where Should We Be In 5 Years And Why</td>
</tr>
<tr>
<td></td>
<td>Edward C. Jauch, MD</td>
</tr>
<tr>
<td>8:57</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

**PART 1B: STATE-OF-THE-ART IMAGING**

**Moderators:** Lawrence Wechsler, MD David S. Liebeskind, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:17</td>
<td>Why Does Clot Location, Composition And Size Really Matter?</td>
</tr>
<tr>
<td></td>
<td>Albert J. Yoo, MD</td>
</tr>
<tr>
<td>9:26</td>
<td>The Neuroimaging Protocol Made Easy: Quick, Accurate And Reliable Anatomic And Physiologic Imaging</td>
</tr>
<tr>
<td></td>
<td>Howard A. Rowley, MD</td>
</tr>
<tr>
<td>9:35</td>
<td>Summarization Of The Latest Trials And Learning Points</td>
</tr>
<tr>
<td></td>
<td>Lawrence Wechsler, MD</td>
</tr>
<tr>
<td>9:48</td>
<td>Collaterals And Definitive Reperfusion</td>
</tr>
<tr>
<td></td>
<td>David S. Liebeskind, MD</td>
</tr>
<tr>
<td>9:57</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>10:15</td>
<td>Break – Visit Exhibits and Pavilions (2nd and 3rd Floors)</td>
</tr>
</tbody>
</table>

**PART 1C: TRIAGE ISSUES AND DEBATES**

**Moderators:** Edward C. Jauch, MD, MS Lawrence Wechsler, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:31</td>
<td>Triage At Its Best: My Brooklyn Pearls</td>
</tr>
<tr>
<td></td>
<td>Steven H. Rudolph, MD</td>
</tr>
</tbody>
</table>
10:39 – 10:46
"Telestroke" 2012: From Far And Away The Specialist Can Make The Difference
TBD

10:47 – 10:53
Why Has Imaging Failed To Find The Optimum Patients For Revascularization?
Lawrence Wechsler, MD

10:54 – 11:00
Best Stroke Imaging Of The Future And Why
Pamela W. Schaefer, MD

PART 1D: ACUTE STROKE TREATMENT
Moderators: Ajay K. Wakhloo, MD, PhD
Joshua A. Hirsch, MD

11:01 – 11:08
IV TPA Recent Updated Guidelines: Does 3, 4, Or 6 Hours Really Have A Basis In The Literature Or In Pathophysiology?
Osama O. Zaidat, MD

11:08 – 11:16
IA Medical Nuances - When And How Much: Does Temporary Stenting Revisit The Need For Thrombolitics
Don Frei, MD

11:17 – 11:23
Thrombectomy: Summary Of The Clotted Data And Outcomes
Aquilla S. Turk, DO

11:24 – 11:31
Antiplatelet Therapy And Beyond: How It Relates To Intracranial Stenting And More
Lucie G. Thibault, Pharm.D

11:32 – 11:39
Angioplasty, Stenting And Temporary Stenting (A True Bridging Protocol): Facts And Fictions: My Opinion!
David Fiorella, MD

11:40 – 11:47
Is It Device Or Patient Criteria That Are Most Important To Make An Impact In Early Revascularization With Efficacy?
Ajay K. Wakhloo, MD, PhD

11:48 – 12:00
Panel Discussion

SESSION 10 (Murray Hill Suites A&B, 2nd Floor)
MULTIDISCIPLINARY ACUTE STROKE MANAGEMENT – PART 2

PART 2A: POWER LUNCHEON SYMPOSIUM: CAROTID AND INTRACRANIAL STENTING: WHAT WENT WRONG WITH THE TRIALS?
Moderators: Thomas G. Brott, MD
Joshua A. Hirsch, MD
Peter K. Nelson, MD
Philip M. Meyers, MD

12:15 – 12:25
CREST: Salient Points And Implications For The Future
Thomas G. Brott, MD

12:26 – 12:36
Facts, Unknowns And Reasons For The Ongoing Controversy About The Best Treatment For Asymptomatic Carotid Stenosis
Frank J. Veith, MD

12:37 – 12:47
Doppler Is Not Enough To Send My Patient For Revascularization And Why: The Neurological Perspective
Don Heck, MD

12:48 – 12:59
Discussion
1:00 – 1:10  SAMMPRIS: Summary From The PI And Future Implications
Colin P. Derdeyn, MD

1:11 – 1:21  SAMMPRIS Results: Why I Advocate A New Trial And Why Patients Need Technology
David Fiorella, MD

1:22 – 1:32  IMS III – Latest Trial Results And Reason To Pause, Or Proceed With New Interest And Ideas: Unofficial Comments
Edward C. Jauch, MD, MS

1:33 – 1:43  Stroke Trials: Lessons Learned: The Next Horizon To Make An Impact On Stroke Reversal Or Prevention
J. Mocco, MD, MS

1:44 – 1:59  Discussion

PART 2B:  THE OTHER SIDE OF STROKE: SUBARACHNOID HEMORRHAGE MANAGEMENT
Moderators: David Gordon, MD  Aquilla S. Turk, DO

2:00 – 2:10  Subarachnoid Hemorrhage: Vasospasm Latest Developments
Aman B. Patel, MD

2:11 – 2:21  Neuroanesthesia: Elements For Success
Apalonia E. Abramowicz, MD

2:22 – 2:32  Latest Devices For Aneurysm Therapy: Are Coils Becoming The Second Option?
Peter K. Nelson, MD

2:33 – 2:43  Surgical Clipping Of Aneurysms Is Still A Necessary Evil: Case Selection From An Experienced Cerebrovascular Neurosurgeon
Eugene S. Flamm, MD

2:44 – 2:54  Endovascular Cases That Make Me Nervous: Location, Geometry, And Beyond
Aaron S. Dumont, MD

2:55 – 3:05  Unruptured Aneurysms: Why Do We Treat Them?
The US Experience vs. The Rest Of The World Opinion
TBD

David J. Langer, MD

3:17 – 3:22  Most Common Medical Legal Issues
Gregg H. Zoarski, MD

3:23 – 3:28  Ways To Avoid Facing The Wrong Side Of The Jury
Michael I. Weintraub, MD

3:29 – 4:00  Discussion

4:00  Adjourn

Visit Exhibits and Pavilions (2nd and 3rd Floors)
CONCURRENT THURSDAY MORNING PROGRAMS

PROGRAM A
(SESSIONS 11 – 13)
Cardiac And Thoracic Aortic Diseases And Their Treatment
6:30 A.M. – 9:54 A.M.
Grand Ballroom East and West, 3rd Floor

PROGRAM B
(SESSIONS 14 – 16)
New Endovascular Approaches To Lower Extremity And Below-Knee Arterial Disease And Its Treatment
6:35 A.M. – 9:54 A.M.
Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 11 – 13)
TOPICS DEALING WITH CARDIAC AND THORACIC AORTIC DISEASES AND THEIR TREATMENT
(GRAND BALLROOM EAST AND WEST, 3RD FLOOR)

6:30 – 6:35
Opening Remarks
Frank J. Veith, MD

SESSION 11 (Grand Ballroom East and West, 3rd Floor)
PROGRESS IN TRANSCATHETER HEART VALVES, NEW APPROACHES TO THE ASCENDING AORTA AND THORACIC AORTIC DISEASE
(5-MINUTE TALKS)
Moderators: Roy K. Greenberg, MD
Peter R. Taylor, MA, MChir

6:35 – 6:40
Transcatheter Aortic Valve Implantation (TAVI) For Unsatisfactory Surgical Valve Implantations: Will It Be An Exception Or The Routine In The Future
Dietmar H. Koschyk, MD

6:41 – 6:46
Why Vascular Surgeons Must Play A Role In TAVI Procedures: Why Is Their Expertise Important
Marc R.H.M. van Sambeek, MD, PhD

6:47 – 6:52
New Developments In Transcutaneous Mitral Valve Repair
Ted Feldman, MD

6:53 – 6:58
Present Status And Future Potential Of TAVI
Martin B. Leon, MD

6:59 – 7:04
Wrapping Procedure For Dilated Ascending Aorta: When And How To Do It
Mario Lachat, MD

7:05 – 7:10
Status Of Endovascular Graft Repair For Aortic Arch Lesions: What Endovascular Solutions Are Working And What Are Not Working
Timothy A.M. Chuter, DM

7:11 – 7:16
Quantifying Ascending Aorta And Arch Deformation From Respiratory And Cardiac Motion: Implications For Branched Devices
Ronald L. Dalman, MD
Retrograde Dissection During Endovascular Treatment Of Aortic Arch Pathology: How Can It Be Prevented And Treated
Germano Melissano, MD
Roberto Chiesa, MD

Risk Factors Of Stroke In Thoracic Endovascular Aortic Repair (TEVAR) And How To Offset Them
Wei Guo Fu, MD

Hybrid Rescue Techniques For Failed TEVAR Procedures
Eric E. Roselli, MD

Panel Discussion

SESSION 12 (Grand Ballroom East and West, 3rd Floor)
NEW DEVELOPMENTS IN TREATMENT OF THE ASCENDING AORTA, ARCH LESIONS AND AORTIC DISSECTIONS (5-MINUTE TALKS)
Moderators: Larry H. Hollier, MD
Richard P. Cambria, MD

Future Of Endovascular Treatment Of Ascending Aortic Lesions
Christoph A. Nienaber, MD, PhD

Unusual Access Routes To The Ascending Aorta And Arch For Endograft Placement: Advantages, Limitations And Precautions
Tilo Koelbel, MD, PhD

Experience With Endograft Treatment Of Ascending Aortic Lesions And Type A Dissections
Matt M. Thompson, MD

Endovascular Graft Treatment Of Type A Dissections: Technique And In What Proportion Of Patients Will It Be Possible
Zaiping Jing, MD

Complete Endovascular Graft Exclusion Of Arch Aneurysms Using A Non-Custom-Made Branched Arch Device (Cook)
Krasni Ivancev, MD, PhD

New Developments In Endovascular Repair Of Zone 0 Aortic Arch Pathologies
Toru Kuratani, MD, PhD

Experience With The Bolton Arch Branch Endograft
W. Anthony Lee, MD

Advantages Of A Precurved Fenestrated Endograft For Treating Arch Aneurysms And Dissections
Yoshitake Yokoi, MD

Hybrid (Open And Endo) Treatment Of Aortic Arch Aneurysms And Dissections: How Laparoscopy Can Help In Evaluating Patients With Malperfusion
Roberto Chiesa, MD

Update On In Situ Fenestration For Arch Repair: Will Endovascular Total Arch Repair Replace Open Techniques
Björn Sonesson, MD, PhD

Panel Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Talk Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:47</td>
<td>Open Surgical vs. Endovascular Treatment Of Thoracic Aortic Pathology In Marfan's Syndrome: Is Endo Safe And When</td>
<td>Roberto Chiesa, MD</td>
</tr>
<tr>
<td>8:53</td>
<td>TEVAR For Type B Aortic Dissections In Marfan's Syndrome Can Work</td>
<td>Chang Shu, MD</td>
</tr>
<tr>
<td>8:59</td>
<td>When Is TEVAR Contraindicated And Open Repair Needed With Thoracic Aortic Lesions</td>
<td>Michael J. Jacobs, MD</td>
</tr>
<tr>
<td>9:05</td>
<td>What Is In And What Is Out With Type B Aortic Dissections And Their Endovascular Treatment</td>
<td>Zhong Gao Wang, MD</td>
</tr>
<tr>
<td>9:11</td>
<td>Long-Term (5-Year) Data On Aortic Remodeling After TEVAR Treatment Of Type B Aortic Dissection Supports Early Intervention</td>
<td>Mark Conrad, MD, Richard P. Cambria, MD</td>
</tr>
<tr>
<td>9:41</td>
<td>Managing Progression Of Aortic Disease After TEVAR: Open Surgery Will Always Be Needed For Some Thoracic And Thoracoabdominal Aneurysms</td>
<td>Hazim J. Safi, MD</td>
</tr>
<tr>
<td>8:58</td>
<td>What Is TEVAR Inadequate Treatment For Type B Aortic Dissections</td>
<td>Götz M. Richter, MD, PhD</td>
</tr>
<tr>
<td>9:29</td>
<td>REVascularization Of The Left Subclavian: When It Is Covered During TEVAR Matters: But Only With Aneurysms Not With Dissections</td>
<td>Matthew M. Thompson, MD</td>
</tr>
<tr>
<td>9:35</td>
<td>REVascularization Of The Left Subclavian: When It Is Covered During TEVAR Only Matters In Exceptional Circumstances</td>
<td>Thomas S. Maldonado, MD</td>
</tr>
<tr>
<td>9:41</td>
<td>Routine REVascularization Of The Left Subclavian For All Zone 2 TEVARs Is Unnecessary And Probably Harmful</td>
<td>Frank J. Criado, MD</td>
</tr>
<tr>
<td>9:47</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>9:54</td>
<td>Break - Visit Exhibits and Pavilions (2nd and 3rd Floors)</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION B** (SESSIONS 14 – 16)

NEW ENDOVASCULAR APPROACHES TO LOWER EXTREMITY AND BELOW-KNEE ARTERIAL DISEASE AND ITS TREATMENT (TRIANON BALLROOM, 3RD FLOOR)

<table>
<thead>
<tr>
<th>Time</th>
<th>Talk Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:35</td>
<td>Opening Remarks</td>
<td>Frank J. Veith, MD</td>
</tr>
</tbody>
</table>
SESSION 14 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS I
(5-MINUTE TALKS)

Moderators: Enrico Ascher, MD
Bruce J. Brener, MD

6:40 – 6:45
DEBATE: 2-3 Year Comparison Of Sirolimus Eluting Stents (SEFs) vs. Bare Metal Stents (BMSs) For Below-Knee And Tibial Occlusive Disease (YUKON Trial)
Gunnar Tepe, MD

6:46 – 6:51
DEBATE: Drug Eluting Balloons (DEBs) Are Better For Below-Knee Lesions Than SEFs: 1-Year Results
Francesco Listro, MD

6:52 – 6:57
Use Of 4 French Systems For Treating Fem-Pop Lesions: Advantages And Disadvantages: Lessons From The 4EVER Trial Using Astron Pulsar Stents And No Closure Devices
Koen Deloose, MD
Marc Bosiers, MD

6:58 – 7:03
New Developments In Distal Puncture Techniques For Treating CTOs Of Lower Extremity Arteries: The Funnel Balloon Catheter, 3 Fr Sheath; Needle Extensions And COR Balloons
Andrej Schmidt, MD, PhD

7:04 – 7:09
Best Treatment Of Popliteal Lesions: Stent vs. PTA: The ETAP Trial
Thomas Zeller, MD

7:10 – 7:15
Value Of The Biodegradable Balloon Expandable Remedy Stent For Lower Extremity Lesions: The GAIA Trial Results
Dirk Scheinert, MD

7:16 – 7:21
Does Atherectomy Help To Treat Resistant Calcified SFA Lesions: Does It Require A Distal Filter For Safety
Daniel G. Clair, MD

7:22 – 7:27
DEBATE: Current Role Of New Atherectomy Devices: They Work And Justify The Costs
James F. McKinsey, MD

7:28 – 7:33
DEBATE: Debubling With Atherectomy And Laser Is A Good Idea Whose Time Has Passed
Frank J. Criado, MD

7:34 – 7:40
Panel Discussion

SESSION 15 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS II
(5-MINUTE TALKS)

Moderators: Kenneth Ouriel, MD, MBA
Evan C. Lipsitz, MD

7:40 – 7:45
Long-Term Evaluation (To 5 Years) Of SFA Stents In 1000 Patients: Importance Of TASC Classification, Stent Type And Lesion Length (Belgian/German Study)
Marc Bosiers, MD
Giovanni Torsello, MD
Patrick Peeters, MD

7:46 – 7:51
The Many Uses And Advantages Of The Supera Veritas Stent (IDEV) To Treat Femoropopliteal Lesions
Peter C.J. Goverde, MD
Dierk Scheinert, MD
1-Year Results Of The Protege Everflex Stent (ev3) To Treat Popliteal Lesions: DURABILITY-POP Study
Patrick Peeters, MD

DEBATE: CFA And DFA Occlusive Lesions Are Best Treated By Endovascular Techniques
Thomas Zeller, MD

DEBATE: How Should CFA And DFA Occlusive Lesions Best Be Treated
Gustavo S. Oderich, MD

Extreme Approaches To CTOs via Retrograde Puncture Of Pedal Loop And Digital Arteries: How To Do It
Marco G. Manzi, MD

DEBATE: Stenting Is Still First Line Treatment For SFA Occlusive Disease
Erich Minar, MD

DEBATE: Why Should Metal Be Avoided In The SFA And How To Do It
Giancarlo Bianino, MD, PhD

How To Remove Small Procedural Emboli From Tibial Arteries
Andrej Schmidt, MD

What To Do For CLI Patients When There Are No Patent Outflow Arteries: Can DEBs Help
Roberto Ferraresi, MD

Panel Discussion

SESSION 16 (Trianon Ballroom, 3rd Floor)
LOWER EXTREMITY HOT TOPICS III
(5-MINUTE TALKS)
Moderators: Jacques Busquet, MD Luis A. Sanchez, MD

DEBATE: Atherectomy And DEBs For Native Disease And In Stent Restenosis In The SFA And Popliteal: Stents Can Be Avoided Completely
Thomas Zeller, MD

DEBATE: DEBs Won’t Do The Job Alone: Stents Will Be Needed Sometimes For Recoil Or Dissection
Dierk Scheinert, MD

The Tack-It Device: An Endovascular Stapler For Imperfect PTAs To Avoid Stenting
Peter A. Schneider, MD

3-Year Results Of The RESILIENT Trial With The Lifestent: Are The Results Of SFA Stents Durable
John R. Laird, MD

3-Year Results From The ZILVER PTX Drug Eluting Stent (DES) Trial: Are The Results Durable And How Do Patterns Of Restenosis Differ
Michael D. Duke, MD Gary M. Ansell, MD

2-Year Outcomes Of Stent Supported PTA For Iliac Lesions: Balloon vs. Self-Expanding Stents: Influence Of TASC Classification: The BRAVISSIMO Trial
Patrick Peeters, MD

DEBATE: To Treat Lower Extremity Chronic Total Occlusions (CTOs) One Only Needs A Wire And A Catheter And Not All This Expensive Nonsense
Amman Bolia, MD
DEBATE: We Need All This Stuff And More To Meet Unmet Needs With Lower Extremity Occlusive Disease
Gary M. Ansel, MD

How To Use A Radiofrequency Wire To Cross Difficult CTOs: Advantages, Precautions, Limitations
Marcelo S. Guimaraes, MD

ALL CLI Is Not The Same: This And Diabetic Status Render Limb Salvage Rates A Poor Index Of Success With Revascularization Procedures: Some Limbs With CLI Survive With Conservative Treatment And Prayer
Francesco Serino, MD

Panel Discussion

Break - Visit Exhibits and Pavilions (2nd and 3rd Floors)

Conclusion of Program B. VEITHsymposium continues in the Grand Ballroom, 3rd Floor.

SESSION 17 (Grand Ballroom East and West, 3rd Floor)
NEW DEVELOPMENTS IN SFA AND CRURAL ARTERY TREATMENT OF CRITICAL LIMB ISCHEMIA (CLI) (5-MINUTE TALKS)
Moderators: Frank J. Veith, MD and Barry T. Katzen, MD

Enrico Ascher, MD

10:16 – 10:21 13 Steps To Successful Pedal Access
Craig M. Walker, MD

10:22 – 10:27 Drug Eluting Balloons (DEBs) Really Work: Comparative Results Prove It: When And Where Are DEBs Indicated
Gunnar Tepe, MD

10:28 – 10:33 How Have DEBs Changed Lower Extremity Interventional Practice In Germany: Above And Below The Knee
Andrey Schmidt, MD

10:34 – 10:39 How DEBs Have Changed Lower Extremity Interventional Practice In Italy: Are They Worth The Increased Cost
Giancarlo Biamino, MD, PhD

10:40 – 10:45 Head-To-Head Comparison Of DEBs And DESs In Below Knee Arteries And After In Stent Restenosis: Which Is Best
Konstantinos Katsanos, MSc, MD, PhD

10:46 – 10:51 Differences In Amputation Rates Following Treatment For Tissue Loss (Gangrene) And Rest Pain: Their Importance In Trials Evaluating Stem Cell And Other New Treatments
Thomas F. O’Donnell, Jr., MD

10:52 – 10:57 Why Are DESs Not Going To Work In CLI Patients Based On The Anatomy Of Their Lesions
Nicholas A. Diehm, MD

11:00 – 11:03 The Case For Subintimal PTA Above And Below The Inguinal Ligament
George H. Meier III, MD
Open Bypass Procedures Have Value And Can Work When Endovascular Interventions Have Failed: What Percentage Of CLI Patients Will Need A Bypass: Endo First Is Not The Way To Go In Some Patients Since Bridges Are Burned
Francesco Spinelli, MD

Pedal Bypasses Are Definitely Superior To PTA For Long Tibial Lesions
Werner Lang, MD

Wound Related And Flow Guided Treatment For CLI With Necrotic Foot Lesions
Roberto Ferraresi, MD

DEBATE: The Case For The Angiosome Concept
Richard F. Neville, MD

DEBATE: The Angiosome Concept Is Not Important Except Possibly In Dialysis Patients
Nobuyoshi Azuma, MD

DEBATE: A Patent Pedal Arch Is More Important Than The Angiosome Concept: But Foot Healing Can Occur Without An Intact Pedal Arch
Hisham Rashid, MSc

Indocyanine Green Angiography: A Method To Study The Angiosome Concept
Joseph L. Mills, MD

Stem Cell Therapy Will Have An Increasing Role In The Treatment Of CLI: It Really Works And A Glimpse Into The Future: Based On The RESTORE CLI Phase 2b Trial
Richard J. Powell, MD

Panel Discussion

1:00 P.M. – 6:55 P.M.

Program C (Sessions 18 – 22)
TEVAR, EVAR (18); Carotid Stenting (19); (20) Lower Extremity Stent-Graft; Vascular Disease And CCSVI For MS (21); Endoleaks (22)
1:00 P.M. – 6:55 P.M.
Grand Ballroom East, 3rd Floor

Program D (Sessions 23 – 25)
Short Topics Relevant To Other Parts Of Program C On Lower Extremity (23); Thoracic And Abdominal Aorta (24); Miscellaneous And CCSVI (25)
1:00 P.M. – 5:45 P.M.
Grand Ballroom West, 3rd Floor

Program C (Sessions 18 – 22)
Session 18 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN TEVAR AND EVAR (5-MINUTE TALKS)

Moderators: Juan C. Parodi, MD
           Hazim J. Safi, MD

1:00 – 1:05
Axillofemoral Bypass To Prevent Limb Ischemia During Prolonged Iliac Sheath Occlusion For Complex EVARs
Krassi Ivancev, MD, PhD

1:06 – 1:11
Lessons Learned And Precautions Needed With Fenestrated And Branched Grafts For Complex Aneurysm Repairs
Piotr M. Kasprzak, MD

1:12 – 1:17
Pathogenesis Of Spinal Cord Ischemia (SCI) During TEVAR And Open Repair: Is It The Same Or Different: Implications For Prevention And Treatment
Charles W. Acher, MD

1:18 – 1:23
How To Prevent SCI After TEVAR
Michael J. Jacobs, MD

1:24 – 1:29
Tips And Tricks For Performing CSF Drainage Optimally With TEVAR Or Open Repair
Vicente Riambau, MD, PhD

1:30 – 1:35
DEBATE: Endovascular Graft Treatment Of Acute Uncomplicated Type B Aortic Dissection May Not Be A Good Idea: Medical Treatment May Be As Good (Video)
Sebastian E. Debus, MD, PhD

1:36 – 1:41
DEBATE: Experience With Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissection: It Really Is The Right Thing To Do Based On False Lumen/True Lumen Measurements
Rodney A. White, MD

1:42 – 1:47
Long-Term (3-5 Year) Results Of The INSTEAD Trial Shows The Benefit Of Early TEVAR Treatment Of Uncomplicated Type B Aortic Dissections: Game Changing Results
Christoph A. Nienaber, MD, PhD

1:48 – 1:53
Results Of TEVAR In Acute Type B Aortic Dissection vs. Best Medical Treatment: First Results Of The ADSORB Trial: A Randomized Controlled Trial
Jan S. Brunkwall, MD, PhD

1:54 – 1:59
Some Concerns After Aortic Endografting For Type B Aortic Dissections
Stephen W.K. Cheng, MBBS

2:00 – 2:05
How Valuable Are The Aptus HeliFX Staples (EndoAnchors): Results From The ANCHOR Registry
William D. Jordan, Jr., MD

2:06 – 2:12
Panel Discussion

SESSION 19 (Grand Ballroom East, 3rd Floor)
CRITICAL EVALUATION OF CAROTID ARTERY STENTING (CAS) IN NOVEMBER 2012: WHERE IS IT AND WHERE IS IT GOING (5-MINUTE TALKS)

Moderators: Giorgio M. Biasi, MD
            Frank J. Veith, MD

2:12 – 2:17
Why MRI Should Be Done Before All Revascularization Procedures (CAS And CEA): Duplex Is Not Enough
Emmanuel M. Houdart, MD
Closed vs. Open Cell Stents For CAS: The Number Of Embolic Particles Are No Greater Nor Are Outcomes Worse With Open Cell Stents
Peter L. Faries, MD

CAS For Total Carotid Occlusion: It Can Work And Be Beneficial: Under What Circumstances
Paul H.L. Kao, MD

DEBATE: CAS Is Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis
Klaus D. Mathias, MD

DEBATE: CAS Is Not Good Treatment For Most Patients With Symptomatic And Asymptomatic Carotid Stenosis
Bruce A. Perler, MD, MBA

Is Current Best Medical Treatment (BMT) Feasible And Does It Work To Decrease Strokes From Intracranial Disease In A High Risk Population: Results From The SAMMPRIS Trial Suggest BMT Can Decrease Strokes Markedly
Marc Chimowitz, MD

Analysis Of CREST By A Neuroradiologist: What Is The Significance Of A Minor Stroke
Emmanuel M. Houdart, MD

DEBATE: Cardiac Events Are An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Improved With Time
William A. Gray, MD

DEBATE: Cardiac Events Are Not An Appropriate End-Point For Evaluating CAS vs. CEA Outcomes; And In CREST, CAS Results Did Not Improve With Time
Wesley S. Moore, MD

Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CEA Are Better Than CAS
Hans-Henning Eckstein, MD, PhD

The Case Against Embolic Protection Devices In CAS: Why Therefore Are They So Widely Used
Michel S. Makaroun, MD

Meta-analysis Of CAS By Cervical Access Shows Dramatic Reduction In Neurological Events
Patrice F. Bergeron, MD
Petrosian Andranik, MD

A Specialized Device For Performing CAS Via A Cervical Approach With Flow Reversal (FAST-CAS System): Early Results From The PROOF Trial
Ralf R. Kolvenbach, MD

DEBATE: Why Is It Difficult To Randomize Asymptomatic Carotid Stenosis Patients To A 3-Armed Trial: CEA vs. CAS vs. BMT
Alison Halliday, MS

DEBATE: Why We Must Have A Trial Comparing BMT To CAS And CEA In Asymptomatic Patients With Carotid Stenosis
Anne L. Abbott, MD, PhD

TCD Embolic Signals, Silent Infarcts On CT-Brain Scans, Or The Size Of Juxtaluminal Black Area In Evaluating Stroke Potential Of Asymptomatic Carotid Lesions
Andrew N. Nicolaides, MS
Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 20 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN LOWER EXTREMITY STENT-GRAFTS (5-MINUTE TALKS)
Moderators: Mark A. Adelman, MD
Darren B. Schneider, MD

4:00 – 4:05
Patency Of Viabahn Stent Grafts Is Better Than Bare Metal Stents For SFA Occlusive Disease: Final Results Of The VIASTAR Trial
Johannes Lammer, MD

4:06 – 4:11
Are Stent Grafts The Solution For In-Stent Restenosis After SFA Stenting
Marc Bosiers, MD
Koen Deloose, MD

4:12 – 4:17
Technical Considerations To Improve Results With SFA Stent-Grafting For Occlusive Disease: Lessons Learned From The VIPER Trial With Heparin-Bonded Viabahn Stent-Grafts
Richard R. Saxon, MD

4:18 – 4:23
Why Do Viabahn Stent-Grafts Fail In The First Year: Does Collateral Coverage And Antiplatelet Treatment Matter
Michael S. Conte, MD

4:24 – 4:29
Standard Fempop Bypasses Are Better Than Endoluminal Stent-Graft "Bypasses" For 5-25 cm SFA Occlusions: An Older RCT: Is It Still Relevant
Mauri J.A. Lepantalo, MD

4:30 – 4:35
Current Status Of Heparin Bonded Viabahn Stent-Grafts Based On European Studies
Thomas Zeller, MD

4:36 – 4:41
Current Status Of Viabahn Endografts For Treatment Of Popliteal Aneurysms: Which Patients Should Not Be Treated Endovascularly
Eric L.G. Verhoeven, MD, PhD

4:42 – 4:47
Can Covered Stents Safely Be Placed Across The Inguinal Ligament And In The CFA
Keith D. Calligaro, MD

4:48 – 4:55
Panel Discussion

SESSION 21 (Grand Ballroom East, 3rd Floor)
NEW OR IMPROVED CONCEPTS IN VASCULAR DISEASE TREATMENT AND THE CONTROVERSY OVER THE INTERVENTIONAL TREATMENT OF CCSVI FOR MULTIPLE SCLEROSIS (5-MINUTE TALKS)
Moderators: Bruce A. Perler, MD, MBA
Jean-Baptiste Ricco, MD, PhD

4:55 – 5:00
Tips And Tricks For Vascular Disease Intervention In Pediatric Patients
Furuzan Numan, MD

5:01 – 5:06
DEBATE: Update On The Treatment Of Vascularogenic Impotence: Viagra, Cialis And Levitra Are Most Often Enough
Ralph G. DePalma, MD

5:07 – 5:12
DEBATE: Not True, Some Patients Need Internal Pudendal Stenting: Current Status Of The Endovascular Treatment Of Erectile Dysfunction
Krishna J. Rocha-Singh, MD
The CCSVI Controversy In Multiple Sclerosis

5:13 – 5:18 What's New In The Diagnosis And Endovascular Treatment Of CCSVI In MS Patients
Paolo Zamboni, MD

5:19 – 5:24 Endovascular Treatment Of CCSVI In MS Patients Really Works: The Benefits Of Treating Venous Brain Congestion Can Be Documented
Ivo Petrov, MD, PhD

5:25 – 5:30 The Benefits Of Treating CCSVI In MS Are Likely Due To A Placebo Effect: A Skeptical Neuro-Interventionalist's View
Kieran Murphy, MD

5:31 – 5:36 Intrinsic And Extrinsic Cerebrospinal Venous Abnormalities In Neurological Diseases: Anatomic And Physiological Evidence
Michael D. Dake, MD

Manish Mehta, MD, MPH

5:43 – 5:48 DEBATE: The Case Against Treating CCSVI In MS Patients
Emmanuel M. Houdart, MD

5:49 – 5:54 DEBATE: The Case For Treating CCSVI In MS Patients
Donald B. Reid, MD

5:55 – 6:00 DEBATE: Venous Angioplasty For MS Is Voodoo Medicine
Mark H. Wholey, MD

6:01 – 6:06 Panel Discussion

SESSION 22 (Grand Ballroom East, 3rd Floor)

NEW OR BETTER TECHNIQUES FOR TREATING ENDOLEAKS AND OTHER EVAR AND TEVAR TOPICS (5-MINUTE TALKS)

Moderators: Timur P. Sarac, MD Luis A. Sanchez, MD

6:06 – 6:11 How And When Is It Safe To Treat Type I Endoleaks After EVAR Non-Interventionally: A 13-Year Experience
James May, MD, MS

6:12 – 6:17 How Embolization With Onyx Can Be An Effective Solution For Type I Endoleaks And Other Novel Solutions For Endoleaks After EVAR And TEVAR
Robert A. Morgan, MD

6:18 – 6:23 Long-Term Follow-up Of Treated Type II Endoleaks Shows The Need For Close Surveillance And Frequent Re-Treatment
Timur P. Sarac, MD

6:24 – 6:29 When Does Translumbar Glue Embolization Of Type II Endoleaks Work And When Does It Not: Tips And Tricks To Make It Effective
Neal S. Cayne, MD

6:30 – 6:35 Tips And Tricks On How To Use Onyx In The Treatment Of Type I And Other Major Endoleaks
Thomas Larzon, MD

6:36 – 6:41 The Anaconda Fenestrated Graft For Juxtarenal AAAs: Advantages, Limitations And 1-Year Registry Results
Nick J. Burfitt, BSc, MB, BChir, MRCS
Interplay Between Anatomy And Indications (Pathology) In TEVAR Outcomes: Anatomic Complexity Drives Outcomes More Than Indications (Pathology)
Michael C. Stoner, MD

Panel Discussion
Conclusion of Program C.

PROGRAM D (SESSIONS 23 – 25)
SHORT TOPICS RELEVANT TO OTHER PARTS OF THE PROGRAM ON LOWER EXTREMITY, THORACIC AND ABDOMINAL AORTA; MISCELLANEOUS AND CCSVI (GRAND BALLROOM WEST, 3RD FLOOR)
SESSION 23 (Grand Ballroom West, 3rd Floor)
LOWER EXTREMITY ADDITIONAL TOPICS (4-MINUTE TALKS)

Moderators: Peter L. Faries, MD Ross Milner, MD

1:00 – 1:04 Bringing Atherectomy To The Next Level: What Is Its Future
Jos C. van den Berg, MD, PhD

1:05 – 1:09 Optical Coherence Tomography Of The Femoral Arteries: How Is It Done And What Is Its Value
Konstantinos Katsanos, MSc, MD, PhD

1:10 – 1:14 Will Plaque Excision By Atherectomy Become The Treatment Of Choice For Popliteal Occlusive Disease: 1-Year Results From The DEFINITIVE LE Trial In 800 Patients
James F. McKinsey, MD

1:15 – 1:19 The True Path Rotating Tip Device For Crossing Chronic Total Occlusion (CTO): How Does It Work And How Well Does It Work
John R. Laird, MD

1:20 – 1:24 Relevance Of In-Stent Restenosis In Various Territories And Best Strategies For Treatment
John R. Laird, MD

1:25 – 1:29 Laser Debubling And DEB For In-Stent Restenosis
Jos C. van den Berg, MD, PhD

1:30 – 1:34 The Wildcat Catheter From Avinger In Crossing Difficult Aortoiliac Occlusions
Patrick E. Muck, MD

1:35 – 1:39 Status Of Biodegradable Stents And Will They Work In The Periphery
Ron Waksman, MD

1:40 – 1:44 Long-Term Results Of The ABSORB Trial Showing Benefits Of Biodegradable Coronary Stents: When Will We Know If They Will Work Elsewhere
Lewis B. Schwartz, MD

1:45 – 1:49 Heparin Bonded Bypass Grafts, Stent-Grafts And Hybrid Grafts: Will They Make A Difference
Edward Y. Woo, MD

1:50 – 1:54 Improved 3-Year Patency Of Heparin Bonded PTFE Grafts vs. PTFE Grafts Without Heparin
Russell H. Samson, MD, RVT

1:55 – 1:59 Best Treatment For In-Stent Restenosis After Renal Artery Stenting
Robert A. Lookstein, MD

2:00 – 2:04 Current Optimal Treatment For Long SFA Occlusions
Gary M. Arsel, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:05</td>
<td>Tips And Tricks For Successful Stent-Graft Treatment Of Popliteal Aneurysms</td>
</tr>
<tr>
<td>2:10</td>
<td>Is Functional Popliteal Entrapment A Myth Or Reality</td>
</tr>
<tr>
<td>2:15</td>
<td>Prior Contralateral Major Amputation Predicts Worse Outcomes For Lower Extremity Revascularization In The Intact Limb</td>
</tr>
<tr>
<td>2:20</td>
<td>Outcomes Of Single Segment Greater Saphenous Vein Graft Bypasses Are Better Than Those Of Alternative Autologous Vein Bypasses</td>
</tr>
<tr>
<td>2:25</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

**SESSION 24 (Grand Ballroom West, 3rd Floor)**

**ADDITIONAL THORACIC AND ABDOMINAL AORTA TOPICS (4-MINUTE TALKS)**

**Moderators:** Jerry Goldstone, MD, Gary Giangola, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30</td>
<td>How Much Does Stent Design Matter For The Various Thoracic Aortic Pathologies: What Are The Unmet Needs</td>
</tr>
<tr>
<td>2:35</td>
<td>Initial Experience With Ascending Aortic Endografting Using The Cook Endograft For Type A Dissection</td>
</tr>
<tr>
<td>2:40</td>
<td>Do Distal Bare Stents Have Value In The Treatment Of Type B Aortic Dissections</td>
</tr>
<tr>
<td>2:45</td>
<td>The Embrella Aortic Arch Embolic Deflector: Does It Work: What Precautions Must Be Used And What Are Its Complications</td>
</tr>
<tr>
<td>2:50</td>
<td>New Classification System For Blunt Traumatic Aortic Injury To Guide In Conservative Or Endograft Treatment</td>
</tr>
<tr>
<td>2:55</td>
<td>Pros And Cons Of Early TEVAR With Extensive Coverage Of The Thoracic Aorta In Type B Aortic Dissections</td>
</tr>
<tr>
<td>3:00</td>
<td>Diagrams Showing How To Make Sandwich Grafting Technique Work For Endovascular Treatment Of Thoracoabdominal Aneurysms</td>
</tr>
<tr>
<td>3:05</td>
<td>How Do Pressure Changes In The Excluded Aneurysm Sac Impact On Spinal Cord Ischemia After TEVAR</td>
</tr>
<tr>
<td>3:10</td>
<td>How Do Outcomes From A Contemporary EVAR Registry (ENGAGE Registry) Differ From Those From Older Registries Like EUROSTAR: EVAR Is Getting Better</td>
</tr>
<tr>
<td>3:15</td>
<td>Decreasing Prevalence Of AAAs And Improving Short-Term And Long-Term Outcomes After EVAR In Sweden: What Are The Reasons For Them</td>
</tr>
</tbody>
</table>

THURSDAY SESSIONS 23–24
SESSION 25 (Grand Ballroom West, 3rd Floor)
MISCELLANEOUS IMPORTANT TOPICS
(4-MINUTE TALKS)
Moderators: Michael D. Dake, MD, Krassi Ivancev, MD, PhD

**The CCSVI Controversy In Multiple Sclerosis**

4:00 – 4:04 Does Interventional Treatment Help MS Patients: A Skeptical Vascular Surgeon Remains Skeptical
Jean-Baptiste Ricco, MD, PhD

4:05 – 4:09 What’s Happening To The Randomized Trials Comparing Interventional Treatment To Placebo Treatment Of CCSVI In MS Patients
L. Nelson Hopkins, MD

4:10 – 4:14 Incidence Of Internal Jugular Vein Stenosis In Thoracic Outlet Syndrome Patients: How Does This Relate To MS And CCSVI
Sam S. Ahn, MD, MBA

4:15 – 4:19 Are Venous Anomalies In MS Patients Relevant Or Not
Alan H. Davies, MA, DM

4:20 – 4:24 MS And CCSVI: Is The Relationship Real And Causally Important
Andrew N. Nicolaides, MS

4:25 – 4:29 Anatomical Challenges In CCSVI: What Is Their Meaning
Ziv J. Haskal, MD

**More About Abdominal And Thoracoabdominal Aneurysms**

4:30 – 4:34 New Classification Of Suprarenal Aneurysms Based On Location Of The Proximal Seal Zone: Correlates With Mortality And Morbidity Of Fenestrated And Branched Endografts
Krassi Ivancev, MD, PhD
Is Medical Treatment To Slow Growth Of AAAs Effective: The STOPS Trial
Ronald L. Dalman, MD

An Improved Method For Measuring AAA Size With EKG Gated 3D Ultrasound
Henrik Sillesen, MD, DMSc

What Is The “Best” Treatment For Perigraft Hygroma With AAA Sac Enlargement After EVAR
John Blebea, MD, MBA

Novel Method For Making Cannulation Of The Contralateral Limb Quick (<10 Seconds) And Easy During EVAR
Willem Wisselink, MD

Panel Discussion

Miscellaneous Topics

Moderators: John B. Chang, MD
Elliot L. Chaikof, MD, PhD

Details Of “Best” Medical Treatment To Prevent Stroke
Anne L. Abbott, MD, PhD

Managing Complications Of CAS
Klaus D. Mathias, MD

Stroke Prevention And PFO Closure: Dead Or Alive
William A. Gray, MD

Catheter Directed Thrombolysis As Treatment For Acute SMA Occlusion
Björn Sonesson, MD, PhD
Martin Björck, MD, PhD
Timothy A. Resch, MD, PhD

Novel Endovascular Techniques For Treating Complex Iliac Aneurysmal Disease
Joseph L. Mills, MD
Luis R. Leon, MD, RVT

Laparoscopic Sutureless Aortobifemoral Bypass Using The Lachat Viabahn (VORTEC) Technique
Ralf R. Kolvenbach, MD

How Do Long Bare Metal SFA Stents Perform: The DURABILITY Trial Clinical Outcomes, Treadmill Data, Objective Patency, And Routine Stent Fracture Assessment
Jon S. Matsumura, MD

Homocysteine Is A Predictor Of Vascular Mortality: A Useful Marker Misunderstood
Afshin Assadian, MD

Recruitment Of Research Subjects With Social Electronic Media
Grayson H. Wheatley, MD

Use Of Duplex Ultrasound To Facilitate Distal Tibial And Pedal Access To Treat Lower Extremity Occlusive Disease
Jihad A. Mustapha, MD

Panel Discussion

Conclusion of Program D.
FRIDAY, NOVEMBER 16, 2012

6:00 A.M. General Registration – 2nd Floor Promenade
Faculty Registration – Morgan Suite – 2nd Floor
Continental Breakfast – Sutton Complex, 2nd Floor

CONCURRENT FRIDAY MORNING PROGRAMS

PROGRAM E
(SESSIONS 26 – 29)
New Techniques And Technologies (26); TAAAs And CHIMPS (27); Lower Extremity Ischemia – CLI (28); Medical Therapy And Medical Problems (29)
6:40 A.M.– 12:00 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM F
(SESSIONS 30 – 32)
Miscellaneous Hot Topics Related To Lower Extremity And Aortic Disease (30); Venous Topics (31-32)
6:45 A.M. – 12:00 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM E (SESSIONS 26 – 29)
(GRAND BALLROOM EAST, 3RD FLOOR)
SESSION 26
(Grand Ballroom East, 3rd Floor)
NEW TECHNIQUES AND NEW ENDOVASCULAR TECHNOLOGY (5-MINUTE TALKS)
Moderators: Nicholas J. Morrissey, MD
Michael L. Marin, MD

6:40 – 6:45
Use Of Microbubbles In The Treatment Of Acute Arterial Occlusions: How Do They Work And Do They Have Clinical Value
Willem Wisselink, MD

6:46 – 6:51
How The Art-Assist Pneumatic Compression Device Can Heal Ulcers From CLI And Relieve Rest Pain Noninvasively
Andrew N. Nicolaides, MS

6:52 – 6:57
A New Device For Topical Intermittent Compression And Hyper-Oxygenation To Improve Healing Of Infected Ischemic Foot Wounds
Magdiel Trinidad-Vasquez, MD

6:58 – 7:03
Christopher J. Kwolek, MD
Richard P. Cambria, MD

7:04 – 7:09
Use Of Pressure Wire And CO₂ Angiography To Make Renal Artery Stenting Safer And Better
Kim J. Hodgson, MD

7:10 – 7:15
Predicting The Results Of Interventional Treatment Using Computational Analysis Of Blood Flow And Lesion Resistance From CT Data: Is FFR (Fractional Flow Reserve) Applicable To Peripheral Arteries As Well As Coronaries
Christopher K. Zarins, MD

7:16 – 7:21
Progress In Techniques For Treating Below-Elbow Occlusions For Critical Hand Ischemia
Roberto Ferraresi, MD
Management Of Median Arcuate Ligament: A New Treatment Paradigm Including Laparoscopic Ligament Division
Bauer E. Sumpio, MD, PhD

Panel Discussion

SESSION 27 (Grand Ballroom East, 3rd Floor)
THORACOABDOMINAL AORTIC ANEURYSMS (TAAAs) AND TECHNIQUES TO REVASCULARIZE RENAL AND VISCERAL ARTERIES: CHIMNEYS, PERISCOPES AND SANDWICH GRAFTS (CHIMPS) (5-MINUTE TALKS)

Moderators: Mark A. Adelman, MD
Frank J. Veith, MD

Why Parallel Grafts (CHIMPS) Work And Why A Double D Configuration Can Be Achieved With Elimination Of Gutter Endoleaks: Theoretical Considerations And How To Calculate The Right Sizes Of The Parallel Grafts
Jerry Matteo, MD

Long-Term Results After Chimney And Periscope Grafts Up To 7 Years: Are They Durable And How To Make Them Work Well For Pararenal And TAAAs
Mario Lachat, MD
Dieter O. Mayer, MD
Zoran Rancic, MD, PhD

Tips And Tricks For Getting Good Results With CHIMPS: When Fenestrated vs. When CHIMPS
Giovanni Torsello, MD
Konstantinos Donas, MD

Long-Term Results After Sandwich Grafts For TAAAs: Where And When Do They Work And What Precautions Must Be Taken
Armando C. Lobato, MD, PhD

How To Repair Juxtarenal AAAs Safely And Effectively With Double Chimney Grafts: Technique And Results
Jason T. Lee, MD
Ronald L. Dalman, MD

Branched And Fenestrated Grafts Are Best: But What TAAAs Can’t Be Treated With Them And Can Sandwich Grafts Solve The Problem
Martin Malina, MD, PhD

DEBATE: CHIMPS Are Better And Cheaper Than Branched And Fenestrated Grafts For Treating Complex Aneurysms: CHIMPS Will Always Have A Major Role
Ralf R. Kolvenbach, MD

DEBATE: CHIMPS Are Inferior To Branched And Fenestrated Grafts For Complex Aneurysms: Long-Term Results Will Prove It: CHIMPS Will Have Only A Minor Role
Stephan Haulon, MD

Fenestrated And Branched Grafts For EVAR: How Well Have They Performed In France When Used Widely: Based On A National Audit
Jean-Pierre Becquemin, MD
8:33 – 8:38 Role Of Endo, Open And Hybrid For TAAAs: When Is Open Repair Still Best  
Michael J. Jacobs, MD

8:39 – 8:44 Advanced Techniques For Performing EVAR With Difficult Anatomy: How To Avoid Brachial Access When Placing Chimney Or Periscope Grafts  
David J. Minion, MD

8:45 – 8:50 Off-The-Shelf Bifurcated EVAR Grafts For TAAAs: Does It Hold Up And How To Get A Double D Configuration With Seal Of Parallel Grafts  
Karthikeshwar Kasirajan, MD

8:51 – 8:56 Late Results With Physician Modified Stent Grafts For Pararenal And TAAAs: They Are As Good As Manufactured Grafts If . . .  
Gustavo S. Oderich, MD

8:57 – 9:02 A New Simpler Device For Juxtarenal AAAs  
Marcelo Ferreira, MD

9:03 – 9:20 Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 28 (Grand Ballroom East, 3rd Floor) NEW DEVELOPMENTS IN THE TREATMENT OF LOWER EXTREMITY ISCHEMIA AND CLI (5-MINUTE TALKS)
Moderators: Peter F. Lawrence, MD  
Gregg S. Landis, MD

9:20 – 9:25 Long-Term Results With Drug Eluting Balloons (DEBs): Summary Of The Available Trials With Up To 5-Year Results Of THUNDER, DEBATE And PACIFIER Trials With Paclitaxil Coatings  
Gunnar Tepe, MD

9:26 – 9:31 Long-Term (2-5 Years) Results Of SFA Stent Performance In 1000 Patients (A Belgium/Germany Registry Report)  
Giovanni Torsello, MD  
Marc Bosiers, MD

9:32 – 9:37 Promising 1-Year Patency Results For A New Prosthetic Graft (The Fusion Graft) For Above Knee Femoropopliteal Bypass: The PERFECTION Trial  
Hans-Henning Eckstein, MD, PhD  
Afsin Assadian, MD

9:38 – 9:43 Extremity Arterial Reconstruction In Children: Tips And Precautions  
James C. Stanley, MD  
Jonathan Eliason, MD

9:44 – 9:49 DEBATE: All CLI Patients Should Be Treated First By Endovascular Techniques  
Gary M. Ansel, MD

9:50 – 9:55 DEBATE: Some CLI Patients Should Be Treated By A Bypass First: Which Ones And Has Anything Changed In The Past Year  
Michael S. Conte, MD

9:56 – 10:01 Pros And Cons Of Bypass And PTA For Treatment Of Intermittent Claudication From SFA Occlusive Disease: Does Bypass Still Have A Role  
Marc L. Schermerhorn, MD

10:02 – 10:07 Endovascular Treatment Of Infrainguinal Bypass Failure And Impending Failure  
Nicholas A. Diehm, MD
3-Year Findings Of A RCT Comparing Heparin Bonded And Standard PTFE Grafts In Infragenual Bypasses: Is The Benefit Of Heparin Bonding Durable
Jes S. Lindholt, MD

Pedal Bypass To Deep Vein For CLI Can Be Effective Treatment For Extensive Ischemic Ulcer With No Suitable Outflow Artery: Tips And Tricks To Make It Work
Pramook Mutirangura, MD

Nordic Pole Walking Can Improve Intermittent Claudication And Cardiac Fitness: What Is It And How Does It Work
Jonathan D. Beard, MD

Will Stem Cell Treatment Work For CLI: The HARVEST Bone Marrow And Astrom IX MELCELL Trials
Richard J. Powell, MD
William A. Marston, MD

For Claudication From Aortoiliac Occlusive Disease, Supervised Exercise Produces More Relief Than Best Medical Therapy Or Stenting: Results Of The CLEVER Trial
Anthony J. Comerota, MD

Platelet Activity And Optimizing Antiplatelet Treatment: The Next Frontier In Vascular Disease Management
Jeffrey S. Berger, MD, MS

What’s New With Endovascular Ablation Procedures For Atrial And Ventricular Arrhythmias
Larry Chinitz, MD

Christos D. Liapis, MD

What’s All This Hoopla About Statins And Mental Fogginess, Increased Blood Sugar And Diabetes: Should It Make A Difference In Statin Usage Or Is It A Witch Hunt
Don Poldermans, MD

New Concepts Regarding The Importance Of Plaque Instability And Stability In Coronary And Vascular Disease: How Instability Should Be Determined And Treated
Gregg W. Stone, MD

High Incidence Of Asymptomatic Elevated Troponin Levels (Troponin-Only MIs) After Open Vascular Surgery: What Does It Mean And What Can Be Done To Decrease It
Caron B. Rockman, MD

DEBATE: Why We Should Not Stop Screening For Asymptomatic Carotid Stenosis
Glenn Jacobowitz, MD
DEBATE: We Should Stop Screening For Asymptomatic Carotid Stenosis Even Though There Is A Substantial Incidence Of Silent Cerebral Events In These Patients: What Should We Do About It
Alan H. Davies, MA, DM

DEBATE: What’s New About The Role Of Cilostazol In Patients With Vascular Disease: What Are Some Of Its Newly Found Benefits
Anthony J. Comerota, MD

DEBATE: Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: Yes, It Decreases Risk And Is Cost Effective
Don Poldermans, MD

DEBATE: Should Vascular Patients Be Taking A Polypill (Or Multiple Pills) For Secondary Prophylaxis: No, It Is Too Dangerous; Better To Wait For Symptoms
Erich Minar, MD

Panel Discussion

Lunch Break – Americas Hall 1, 3rd Floor
Visit Exhibits and Pavilions (2nd and 3rd Floors)
What Percent Of Diabetics With CLI Can Undergo Revascularization: With PTA: With Bypass
Giacomo Clerici, MD

Use Of OCT (Optical Coherent Tomography) For Crossing Chronic Total Occlusions
Tony S. Das, MD

Panel Discussion

Moderators: Roger M. Greenhalgh, MD
Ali F. AbuRahma, MD

Aortic Topics

A New One-Shot Aortic Occlusion Balloon
Benjamin W. Starnes, MD

3D Imaging And Robotic Catheter Navigation: How Can They Work Together To Facilitate Complex Aortic Procedures
Alan B. Lumsden, MD

DEBATE: The Long-Term Results Of Open Repair Are Better Than Those Of EVAR In Most Patients
Wilhelm Sandmann, MD

DEBATE: The Long-Term Results Of EVAR Are Better Than Those Of Open Repair: The EVAR I Late Results Have Been Misinterpreted In The NEJM Article
Juan C. Parodi, MD

DEBATE: The Results Don’t Justify It
Andres Schanzer, MD

DEBATE: IFUs For EVAR Should Not Be Stretched: The Results Don’t Justify It
William D. Jordan, Jr., MD

DEBATE: Bare Stents Are The Best Treatment For Most Adult Aortic Coarctations: Why Is This So
Christoph A. Nienaber, MD, PhD

DEBATE: Covered Stents Are The Best Treatment For Most Adult Aortic Coarctations
 Dietmar H. Koschyk, MD

Update On Use Of Atrium Advanta V12 Balloon Expandable Stent-Grafts For Treatment Of Aortic Coarctation: Advantages, Limitations And Precautions: From The OUS Trial
Elchanan Bruckheimer, MBBS

Are Fenestrated And Branched Endografts A Better Option For Treating Chronic Type B Aortic Dissections And Associated Aneurysms
Stephan Haulon, MD

Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 31 (Grand Ballroom West, 3rd Floor)
PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART IA (5-MINUTE TALKS)
Moderators: Mark H. Meissner, MD
Lowell S. Kabnick, MD

09:25 – 9:30
Current Treatment For Giant A-V Fistulas Of Renal And Visceral Vessels: Is Endovascular Treatment Feasible And How
Peter Głowiczki, MD

09:31 – 9:36
Current Optimal Surgical Treatment Of Phlegmasia Cerulea Dolens
Kamphol Laohapensang, MD

09:37 – 9:42
Incidence Of Upper Extremity DVT After Central Venous Catheter Placement: Implications And What To Do About It
Gregory L. Moneta, MD

09:43 – 9:48
Superior Vena Cava Aneurysm: Natural History And Indications For Treatment
J. Lionel Villavicencio, MD

09:49 – 9:54
Venous Aneurysms: What Are They And Are They Dangerous: Rupture Risk Has Been Exaggerated And Not All Need To Be Repaired
Jerry Goldstone, MD

09:55 – 10:00
Tips And Tricks For Iliac Vein And IVC Stenting: Access, Crossing Lesions, Stent Choice And Size
Ramesh K. Tripathi, MD

10:01 – 10:06
Current Status Of Stenting For Iliac Vein And Caval Disease: Indications, Which Stent Is Best, Precautions
Sheshadri Raju, MD
Peter Neglen, MD, PhD

10:07 – 10:12
Iliac Vein Stenting For Advanced Chronic Venous Disease: When Will It Improve Symptoms And When Will It Not: Is IVUS Essential
Anil P. Hingorani, MD
Enrico Ascher, MD

10:13 – 10:18
Connecticut Experience With Wall Stenting For Iliac Vein Disease Under IVUS Control: Raju And Neglen Are Right
Paul J. Gagne, MD

10:19 – 10:24
What Is A Saphenous Vein Aneurysm And How Should It Be Treated
Ronald G. Bush, MD

10:25 – 10:35
Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)
PROGRESS IN THE TREATMENT OF VENOUS DISEASE – PART 1B (5-MINUTE TALKS)
Moderators: Bo G. Eklof, MD, PhD
Jose I. Almeida, MD, RVT

10:35 – 10:40
Current Optimal Management Of Paget-Schroetter’s Syndrome
George H. Meier III, MD

10:41 – 10:46
Upper Extremity DVT: Early Lysis And Rib Resection Improves Outcomes
Ian Loftus, MD

10:47 – 10:52
1-Stage Aggressive Treatment Of Paget-Schroetter Syndrome: What Does It Involve And Why Is It Best
Karl A. Illig, MD
SESSION 33 (Grand Ballroom East, 3rd Floor)
MORE ON TEVAR, TAAAAs AND PARARENAL ANEURYSMS, THEIR TREATMENT AND THE MULTILAYER STENT (5-MINUTE TALKS)
Moderators: Ronald M. Fairman, MD
Mark A. Adelman, MD

1:00 – 1:05
Fenestrated And Branched Grafts To Repair Visceral Patch Aneurysms After Open TAAA Repair
James H. Black III, MD

1:06 – 1:11
Risk Stratification And Prediction Of Long-Term Success After TEVAR For Thoracic Aneurysm Based On THE MOTHER Registry
Matt M. Thompson, MD

Topics Related To The Multilayer Flow Modulating Stent

1:12 – 1:17
Value Of The Cardiatis Multilayer Flow Modulating Stent For The Treatment Of Non-Aortic Aneurysms
Antonella Ruffino, MD
Claudio Rabbia, MD, PhD

1:18 – 1:23
Does The Multilayer Stent Exclude And Fix Aortic Aneurysms: Summary Of The French Experience
Claude D. Valsis, MD

1:24 – 1:29
Results Of Treatment Of Complex TAAAAs With The Multilayer Uncovered Stent: The Moroccan Experience
Amira Benjelloun, MD

1:30 – 1:35
With TAAAAs, Does The Multilayer Stent Promote Aneurysm Sac Shrinkage And Prevent Rupture: What Is The Evidence
Sherif Sultan, MD
Niamh Hynes, MD

1:36 – 1:41
Chinese Experience With The Multilayer Stent For Treatment Of Complex Aortic Aneurysms
Qingsheng Lu, MD
Zaiping Jing, MD

1:42 – 1:47
Is The Multilayer Stent An Effective Treatment For Arch Aneurysms And TAAAAs: What Happens To Sac Pressure And Aneurysm Size After Treatment: Is Rupture Prevented
Thomas Larzon, MD

1:48 – 1:53
DEBATE: The Multilayer Stent Is Going To Work For The Treatment Of Complex Aortic Aneurysms: Theoretical Considerations And Clinical Experience
Edward B. Diethrich, MD

1:54 – 1:59
DEBATE: The Multilayer Stent Is Not Going To Work For The Treatment Of Complex Aneurysms: Theoretical Considerations
Zvonimir Krajcer, MD

2:00 – 2:05
Another Skeptical View On The Value Of The Multilayer Stent For The Treatment Of Complex Aortic Aneurysms
Piergiorgio Cao, MD

2:06 – 2:12
Panel Discussion
SESSION 34 (Grand Ballroom East, 3rd Floor)
PROGRESS IN VASCULAR IMAGING AND GUIDANCE (5-MINUTE TALKS)
Moderators: Brian R. Hopkinson, ChM
John H. Furtek, BS, RT(r)

2:12 – 2:17 Can Noninvasive Imaging Keep Up With Evolving Technology
Allan W. Reid, FRCR

2:18 – 2:23 All The Things You Can Learn From Transcranial Doppler (TCD) That Most Of Us Don't Know About: A New Look At TCD
Zsolt Garami, MD

2:24 – 2:29 The Value Of Hansen Magellen Robotic Assisted Catheter Manipulation For Complex Aortic Endografting
Nicholas J.W. Cheshire, MD

2:30 – 2:35 Little Known Tips And Tricks For Making CO2 Angiography Work Better Than Commonly Thought
Kyungh Cho, MD

Barry T. Katzen, MD

2:42 – 2:47 IVUS Guided EVAR And TEVAR Is Feasible And Effective: Tips And Tricks
Martin R. Back, MD

2:48 – 2:53 Vascular Imaging Strategies For Patients With Renal Insufficiency Requiring MR Imaging
Barry Stein, MD

2:54 – 2:59 Noninvasive Quantification Of Pressure Gradients And Flow With 4D Flow Sensitive MRI: What Unique Information Can This Technique Tell Us In Aortic Dissection
Jon S. Matsushima, MD
Chris Francois, FRCS

3:00 – 3:05 Encouraging 1-Year Clinical Results With A Spiral Flow Prosthetic Graft In Lower Extremity Bypasses
Nick Shaper, FRCS

3:06 – 3:30 Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM H (SESSIONS 35 – 36)
(Grand Ballroom West, 3rd Floor)
MORE NEW CONCEPTS ABOUT AAA, EVAR AND OTHER TREATMENTS OF AORTIC DISEASE (5-MINUTE TALKS)
Moderators: Timur P. Sarac, MD
Palma M. Shaw, MD

1:00 – 1:05 Fenestrated Cuff-Extender For Treatment Of Migrated Infrarenal Endografts: Midterm Results
Krassi Ivancev, MD, PhD

1:06 – 1:11 Do Most AAA Patients Survive Long Enough To Benefit From Aneurysm Repair
Jack L. Cronenwett, MD

1:12 – 1:17 New Findings Regarding Treatment Of Infection Following AAA Repair By EVAR Or Open Surgery
Laura Capoccia, MD, PhD
Strategies To Minimize Blood Loss During EVAR Procedures And Why It Is Important
Claude Mialhe, MD

Off-The-Shelf Device For Pararenal Aneurysms
Mark A. Farber, MD

How To Place Bifurcated Devices In Patients With Iliac Occlusions
David J. Minion, MD
Mark A. Farber, MD
William D. Jordan, Jr., MD

When Should Thoracic Endografts Be Ballooned: How Can Ballooning Be Harmful
Jean Bismuth, MD

Endovascular Treatment Of Various Pathologic Lesions Involving The Aortic Arch
Dittmar Boeckler, MD

Endovascular Treatment Of Aortic Arch Lesions: What Device Can Be Used To Treat Which Lesions
Nicola Mangiardi, MD

Experience With Endostapling (Aptus HeliFX) For Endograft Fixation: It Really Works With Short Necks In The Abdominal And Thoracic Aorta
Burkhart Zipfel, MD

SESSION 36 (Grand Ballroom West, 3rd Floor)
MORE NEW CONCEPTS AND DATA RELATED TO THORACOABDOMINAL AND PARARENAL ANEURYSMS AND CHIMPS (5-MINUTE TALKS)
Moderators: Timothy A.M. Chuter, DM
Keith D. Calligaro, MD

Intrasac Flow Characteristics Of An Enlarging AAA With A Type II Endoleak After EVAR: What To Do To Fix It
Julio A. Rodriguez-Lopez, MD

How To Eliminate Gutter Leakage After Chimney And Periscope Grafts: Based On An In Vitro Measurement Study
Jan D. Blankenstein, MD

Endograft Type And Sizing For Successful Parallel Endografts Or CHIMPS
David J. Minion, MD

I Have Been Converted: For Some TAAAs Open Surgery Should Be Replaced By Endovascular Treatments: When Should It Not Be
Joseph S. Coselli, MD

Is There A Difference In Outcome Between Double And Triple Or Quadruple Fenestrated Grafts: Findings Of The GLOBALSTAR Registry
Peter L. Harris, MD
S. Rao Vallabhaneni, MD

CHIMPS: How And When Do They Work And When Don't They
Ralf R. Kolvenbach, MD
DEBATE: CHIMPS Will Have A Major Role Even When Fenestrated And Branched Grafts Are Widely Available
Frank J. Criado, MD

DEBATE: The Current State-Of-The-Art In Fenestrated And Branched Endografts: When Widely Available They Will And Should Eliminate The Need For CHIMPS
Roy K. Greenberg, MD
Tara M. Mastracci, MD

What Can Be Expected From Chimney Grafts In Para And Juxtarenal AAAs: Are They As Good As Some Say
Jean-Pierre Becquemin, MD

Tips And Tricks To Make Chimney Grafts Work For Juxta And Pararenal AAAs
Alan M. Graham, MD

A Simple Technique Of Limb Perfusion To Prevent Limb Ischemia From Complex Lengthy EVARs
Timothy A. Resch, MD, PhD

Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

PROGRAM I (SESSIONS 37 – 38: ARTERIAL)
(Grand Ballroom East, 3rd Floor)
SESSION 37
(Grand Ballroom East, 3rd Floor)
UPDATES, CONTROVERSIES AND NEW CONCEPTS IN THE TREATMENT OF RUPTURED AAAs
(5-MINUTES TALKS)
Moderators: Nicholas J.W. Cheshire, MD
Frank J. Veith, MD

Update On Dutch Ruptured AAA RCT Of EVAR vs. Open Repair
Willem Wisselink, MD

DEBATE: We Still Need Level I Evidence To Support Use Of EVAR With Ruptured AAAs: Update On The Findings Of The UK IMPROVE Trial
Janet T. Powell, MD, PhD

DEBATE: We Don’t Need A RCT: All Ruptured AAAs Can Be Treated Endovascularly And The Results Are Excellent
Dieter O. Mayer, MD
Thomas Larzon, MD

EVAR Must Be Part Of Any Ruptured AAA Program: Based On A Consensus Panel Finding
Marc R.H.M. van Sambeek, MD, PhD

Why Open Repair Is Still The Gold Standard For Treatment Of Ruptured AAA
Jürg Schmidli, MD

DEBATE: With Ruptured AAAs The Turn-Down Rate For Treatment Is Key
Matt M. Thompson, MD

DEBATE: Technique Not Turn-Down Rate Is Important: Tips And Tricks To Get Good Outcomes From EVAR For AAAs Short-Term And Long-Term
Mario Lachat, MD
Dieter O. Mayer, MD
Frank J. Veith, MD
4:12 – 4:17 Are Outcomes Of Treatment For Ruptured AAAs Better If A Specialist Vascular Surgeon Is Caring For The Patient Than Some Other Specialist (General Surgeon Or Cardiac Surgeon)
Florian Dick, MD

4:18 – 4:23 Prophylactic Use Of Polypropylene Mesh Overlay In Open Repair For AAAs Decreases The 30% Incisional Hernia Rate
Sebastian E. Debus, MD, PhD

4:24 – 4:29 Is The Transfer Of RAAA Patients To Specialized Centers From Smaller Hospitals Worthwhile: A UK Delphi Consensus Study Shows It Is Under Certain Conditions
Robert J. Hinchliffe, MD

Jesper Swedenborg, MD, PhD

4:36 – 4:41 Degree Of Calcification As A Prognostic Factor For Rupture With AAAs
Clark J. Zeebregts, MD, PhD

4:42 – 4:52 Panel Discussion

SESSION 38 (Grand Ballroom East, 3rd Floor)
NEW LATE BREAKING CONCEPTS AND RESULTS IN AORTIC TRAUMATIC TRANSECTION AND TYPE B AORTIC DISSECTIONS (5-MINUTE TALKS)

Moderators: Edward B. Diethrich, MD
Keith D. Calligaro, MD

4:53 – 4:58 Endovascular Treatment Of Traumatic Aortic Transection In Young Patients: Problems Encountered And How To Solve Them
Giorgio M. Biasi, MD

Mark A. Farber, MD

5:05 – 5:10 10-Year Follow-up Of TEVAR For Traumatic Aortic Transection: How Durable Is The Procedure And The Endograft
Karl H. Orend, MD

5:11 – 5:16 What Happens After TEVAR For Traumatic Aortic Transection
Mark Conrad, MD
Richard P. Cambria, MD

5:17 – 5:22 A New More Accurate Method For Measuring False Lumen Thrombosis (FLTx) In Type B Aortic Dissections: 3D MRI With Blood Pool Contrast Agent Obviates Overestimation Of FLTx
Rachel Clough, MD, PhD
Peter R. Taylor, MA, MChir

5:23 – 5:28 Computational Flow Analysis In Type B Aortic Dissections: Lessons Learned
Zhuo Cheng, PhD

5:29 – 5:34 Volumetric Assessment Of Type B Aortic Dissections On CT Imaging: Can We Predict Which Patients Will Have False Lumen Thrombosis
Frank R. Arko, MD
5:35 – 5:40  DEBATE: Fenestrated And Branched Endograft Solutions Are Better Than A Petticoat Graft (Proximal Covered Stent And Distal Bare Stent) For Complicated Type B Aortic Dissections
Eric L.G. Verhoeven, MD, PhD

5:41 – 5:46  DEBATE: Fenestrated And Branched Endografts Are Not Better Than A Petticoat Graft For Complicated Type B Dissections – Even If Chronic
Germano Melissano, MD
Roberto Chiesa, MD

5:47 – 5:52  Update From The STABLE Trial: The Petticoat Concept Of A Proximal Covered Stent And A Distal Bare Stent Is Supported By Follow-up To 2 Years: When Is The Distal Bare Stent Indicated
Joseph V. Lombardi, MD

5:52 – 6:00  Panel Discussion

FRIDAY
SESSIONS 38–39

SESSION 39 (Grand Ballroom West, 3rd Floor)
MORE PROGRESS IN THE TREATMENT OF VENOUS DISEASE - PART IIA (5-MINUTE TALKS)
Moderators: Joann Lohr, MD
J. Leonel Villavicencio, MD

3:30 – 3:35  Neurological Complications Of Sclerotherapy For Varicose Veins: Incidence And Prevention
Alun H. Davies, MA, DM

3:36 – 3:41  Radiofrequency Treatment Of Perforating Veins For Recalcitrant Venous Ulcers: How To Do It And Does It Help
Peter F. Lawrence, MD

3:42 – 3:47  Local Hyperbaric O₂ To Heal Refractory Venous Ulcers
Sherif Sultan, MD
Niamh Hynes, MD

3:48 – 3:53  Update And Clinical Experience With Biodegradable IVC Filter
David Rosenthal, MD

3:54 – 3:59  Why Routine IVC Filters Should Be Placed In Patients With Massive And Submassive PEs
Gary M. Ansel, MD

4:00 – 4:05  Novel Technique For Removing Retrievable IVC Filter When Its Hook Cannot Be Snared
Benjamin M. Jackson, MD
Ronald M. Fairman, MD

4:06 – 4:11  Non-Lipid Lowering Effects Of Crestor On DVT
Thomas W. Wakefield, MD

4:12 – 4:17  Improved Bioprosthetic Valve For Treatment Of Deep Venous Insufficiency: Value Of Autologous Endothelial Cells
Dusan Pavcnik, MD, PhD

4:18 – 4:23  Superficial Vein Thrombophlebitis: To Treat Or Not To Treat
Joseph D. Raffetto, MD

4:24 – 4:29  How To Decrease The Risk Of Anastomotic Stenosis And Occlusion In Bypasses For Takayasu’s Disease
Byung-Boong Lee, MD

4:30 – 4:40  Panel Discussion
SESSION 40  (Grand Ballroom West, 3rd Floor)
PROGRESS IN ENDOVASCULAR TREATMENT OF MASSIVE AND SUBMASSIVE PULMONARY EMBOLI AND OTHER HOT VENOUS TOPICS – PART IIB (5-MINUTE TALKS)
Moderators: Bo G. Eklof, MD, PhD
Nicholas J. Morrissey, MD

4:40 – 4:45 Ultrasound-Assisted Thrombolysis For Massive And Submassive PE
Nils Kucher, MD
Iris Baumgartner, MD

4:46 – 4:51 New Findings In The Use Of Ultrasound Accelerated Thrombolysis In The Treatment Of Submassive PEs
Tod E. Engelhardt, MD

4:52 – 4:57 Endovascular Treatment Of Massive PE: How And When Should It Be Done
David L. Gillespie, MD

4:58 – 5:03 Update On VORTEX Suction Thrombectomy Catheter To Treat PEs And IVC Thrombi: Clinical Experience, Safety And Precautions
Christopher J. Kwolek, MD

5:04 – 5:09 Does Treatment With The Trellis Mechanical Thrombectomy Device Decrease The Postthrombotic Syndrome After 2 Years: Results Of The ISOL-8 Multicenter Trial
Paul J. Gagne, MD

5:10 – 5:15 Value Of Ultrasound Accelerated Thrombolysis In DVT: When Is It Indicated
Cees H.A. Wittens, MD, PhD

5:16 – 5:21 Update On New Anticoagulants For Venous Thromboembolism Prophylaxis And Treatment
Thomas W. Wakefield, MD

5:22 – 5:27 Should Venous IVUS Be Used In All Serious Leg Swelling Patients To Detect Lymphedema From Venous Disease So It Can Be Treated By Stenting
Seshadri Raju, MD

5:28 – 5:33 New Technique For Deep Venous Valve Reconstruction
Ramesh K. Tripathi, MD

5:34 – 5:39 The Relationship Between Venous And Arterial Disease: Is Venous Disease Really An Arterial Problem
Seshadri Raju, MD

5:40 – 5:45 How Should We Manage The Unretrievable Retrievable IVC Filter
Werner Lang, MD

5:46 – 6:00 Panel Discussion
SESSION 41 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN AAAs AND THEIR TREATMENT (5-MINUTE TALKS)

Moderators: K. Wayne Johnston, MD
Dhiraj M. Shah, MD

6:40 – 6:45 Impact Of A Redeployable AAA Stent-Graft (Gore Excluder C-3) To Improve Proximal Seal In Difficult Anatomy: Does It Make A Difference
Eric L.G. Verhoeven, MD, PhD

6:46 – 6:51 Is A Thick Layer Of Neck Thrombus A Contraindication For EVAR
Hence J.M. Verhagen, MD, PhD

6:52 – 6:57 Final Result Of The PEVAR Trial: A RCT Comparing Percutaneous With Open Access For EVAR
Zvonimir Krajcer, MD

6:58 – 7:03 Open And Endovascular Repair Of Para-Anastomotic Aneurysms
Germano Melissano, MD
Roberto Chiesa, MD

7:04 – 7:09 Transecting The Left Renal Vein For Aortic Surgery: Why, How, When And Why Not
Afshin Assadian, MD

7:10 – 7:15 DEBATE: Laparoscopic Vascular Surgery Should Be Growing And Vascular Surgeons Should Learn It And Do It
Joseph S. Giglia, MD

7:16 – 7:21 DEBATE: Why Laparoscopic And Robotic Aortic Surgery Are Losing Their Appeal And Will Not Become Widespread
Willem Wisselink, MD

7:22 – 7:27 The Rise And Fall Of AAAs: The Decreasing Incidence Of AAAs: What Is The Cause
Frank A. Lederle, MD

7:28 – 7:33 Is EVAR Indicated And Justified For Inflammatory AAAs: When Is It Not
Samuel R. Money, MD, MBA

7:34 – 7:39 Is There A Role For AUI Endografts For EVAR
In 2012: Should One Be In Your Endovascular Tool Box For Emergency Use
Thomas L. Forbes, MD

7:40 – 7:45 Feasibility Of EVAR For Infected AAAs: When Does It Work And When Doesn’t It
Chung-Dann Kan, MD, PhD

7:46 – 7:51 How To Manage Infected Aortic Endografts
Edward Y. Woo, MD
Ronald M. Fairman, MD

7:52 – 7:57 Long-Term Quality Of Life Data After EVAR And Open Repair: From The DREAM Trial: Open Repair Wins And Why
Jan D. Blankensteijn, MD
SESSION 42 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN TREATMENT OF THE AORTA AND ITS BRANCHES (5-MINUTE TALKS)

Moderators: Ross Milner, MD
Jean-Pierre Becquemin, MD

8:13 – 8:18 How Does Transcatheter Intra-arterial Denervation Work: Who Should Be Treated And Who Should Not: Why Is the Artery Not Injured And Are There Dangers From The Treatment
Dierk Scheinert, MD

8:19 – 8:24 What Are The Secondary Benefits – Other Than Reducing Blood Pressure – To Renal Denervation: When Will This Treatment Be Available In The US And How Long Will All Benefits Last
Michael R. Jaff, DO

8:25 – 8:30 Status Of Renal PTA And Stenting After ASTRAL And CORAL: What's New In The Field
Thomas A. Sos, MD

Max Amor, MD

8:37 – 8:42 Long-Term Outcomes Of PTA And/Or Stenting For Renal Fibromuscular Hyperplasia: What Is The Best Treatment
Albeir Y. Mousa, MD
Ali F. AbuRahma, MD

8:43 – 8:48 Best Method To Assess SMA Stents: How Does Duplex Correlate With Pressure Measurements, CTA And Clinical Outcomes
Timothy A. Resch, MD, PhD

8:49 – 8:54 Early And Late Outcomes Of PTA And Stenting Of Celiac And SMA Occlusive Disease: Advantages, Limitations And Results Up To 10 Years
Ali F. AbuRahma, MD

8:55 – 9:00 Can The Results Of Mesenteric Revascularization Improve With Covered Stents And Distal Protection Devices
Gustavo S. Oderich, MD

9:01 – 9:06 How To Treat Isolated SMA Dissections: When Medical vs. Interventional vs. Surgical Therapy
Young Wook Kim, MD

9:07 – 9:13 Panel Discussion

Moderators: Michael B. Silva, Jr., MD
James C. Stanley, MD

9:14 – 9:19 DEBATE: Treatment Of Mid-Aortic Syndrome In Young Adults: Interventional Treatment Is Indicated In Some
Ramesh K. Tripathi, MD

9:20 – 9:25 DEBATE: Interventional Therapy Is Never Indicated For Mid-Aortic Syndrome At Any Age: Open Surgery Is Best
Wilhelm Sandmann, MD

9:26 – 9:31 When Are Reentry Devices And Covered Stents Needed For Iliac Occlusive Lesions
Jorn O. Balzer, MD, PhD
DEBATE: Open Surgery Is Still Needed For Some Aortoiliac Occlusive Lesions: Which Ones
Michel S. Makaroun, MD

DEBATE: Endovascular Treatment Is Best For All Aortoiliac Occlusive Lesions
Martin Malina, MD, PhD

Endovascular Treatment Of Juxtarenal Aortic Occlusions Should Always Be Possible Using Chimneys And Other Adjuncts
Sonia Ronchey, MD
Nicola Mangialardi, MD

Use Of Advanta V12 Covered Stents For Endovascular Reconstruction Of The Aortoiliac Bifurcation To Treat Complex Occlusive Lesions
Michel M.P. Reijnen, MD, PhD
Peter C.J. Goverde, MD

Panel Discussion And Break
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 43 (Grand Ballroom East, 3rd Floor)
FUTURE ISSUES REGARDING HEALTH CARE; CONFLICT OF INTEREST; GOVERNMENT; INDUSTRY RELATIONS; BUSINESS OF MEDICINE; PRACTICE COSTS; AND REIMBURSEMENTS (5-MINUTE TALKS)
Moderators: Julius H. Jacobson II, MD
Kenneth Ouriel, MD, MBA

How To Succeed With A Physician Founded Medical Device Company: The Embrella Device As An Example
Jeffrey P. Carpenter, MD

Physician Focused Tort Reform By Limiting Expert MD Testimony Fees And Taking Other Accountability Measures: We Physicians Can Stop Medical Malpractice Abuses No Matter What The Damned Lawyers Do
O. William Brown, MD, JD

What Will Health Care Reform Mean To Practicing Vascular Surgeons, Hospitals And Surgical Services
Robert M. Zwolak, MD, PhD

What’s Happening With Vascular Reimbursement
Sean P. Roddy, MD

What Is A Vascular Surgeon Worth To A Health Care System: A Look At The Finances Surrounding Vascular Care
Michael C. Stoner, MD

Disclosure And Conflict Of Interest: Have We Gone Too Far Or Not Far Enough
Timothy M. Sullivan, MD

Current Status Of The Physician-Industry Relationship: Update On What The Government, Our Medical Schools And Our Hospitals Are Doing To Separate Doctors From Industry
Barry T. Katzen, MD

What Will Happen In The Effort To Separate Doctors From Industry: Predictions For The Future And What Is Happening In Massachusetts
Richard A. Baum, MD, MPA, MBA
SESSION 44 (Grand Ballroom East, 3rd Floor)
TRIBUTE TO OUR MILITARY (5-MINUTE TALKS)
Moderators: Norman M. Rich, MD
Todd E. Rasmussen, MD

11:43 – 11:48
From The Front Lines To The Ivory Tower And Back: How Advances At Walter Reed National Military Medical Center Are Used At The Front
Robert Craig, DO

11:48 – 11:54
A Brief History Of The Tourniquet In Battle
Norman M. Rich, MD

11:55 – 12:00
Vascular Surgery Lessons Learned After A Decade Of War In Iraq And Afghanistan
Todd E. Rasmussen, MD

SESSION 45 (Grand Ballroom East, 3rd Floor)
LUNCHEON SESSION: NEW OR IMPROVED ENDOVASCULAR DEVICES (5-MINUTE TALKS)
Moderators: Eric L.G. Verhoeven, MD, PhD
Juan C. Farodi, MD

12:01 – 12:06
Update On Advantages And Limitations Of The Lombard AORFIX Graft: When Will It Be Approved In The US
Brian R. Hopkinson, ChM
Mark F. Fillinger, MD

12:07 – 12:12
Worldwide Experience With The Aptus HELIFX Endostaples: Can They Fix Endoleaks And Prevent Aortic Neck Enlargement And Migration
David H. Deaton, MD

12:13 – 12:18
Update On The NELLIX Device For EVAR: Advantages And Limitations
Jeffrey P. Carpenter, MD

12:19 – 12:24
Off-The-Shelf Fenestrated VENTANA Device For Renal Revascularization With Juxta And Pararenal AAAs: Clinical Update And Will In Situ Fenestration Be Possible With Newer Multilayer Stretchable PTFE Endograft Coverings
Daniel G. Clair, MD
Advantages And Limitations Of The INCRAFT From Cordis: 1-Year Clinical Data From The INNOVATION Trial
Dierk Scheinert, MD

Description And Clinical Experience With The Anaconda Fenestrated Endograft For Juxta And Pararenal AAAs
Clark J. Zeebregts, MD, PhD

Worldwide Mid-Term Results (2-Year) Of The Endurant Endograft For AAAs: Does It Expand The Proportion Of Patients Who Can Undergo EVAR Safely And Effectively
Dittmar Boeckler, MD, Michel S. Makaroun, MD

Recent Improvements In The Cook Zenith AAA Endograft: How Do They Make A Difference
Roy K. Greenberg, MD

Worldwide Mid-Term Results (2-Year) Of The Endurant Endograft For AAAs: Does It Expand The Proportion Of Patients Who Can Undergo EVAR Safely And Effectively
Dittmar Boeckler, MD

Panel Discussion

ISSUES RELATED TO TRAINING, CERTIFICATION, SIMULATION, SPECIALTIES, GUIDELINES AND RANDOMIZED CONTROLLED TRIALS
(5-MINUTE TALKS)
Moderators: Mario Lachat, MD
Karl A. Illig, MD

What’s New With Maintenance Of Certification (MOC) Requirements For Vascular Surgeons
Anton N. Sidawy, MD, MPH

Recent Developments In The Evolution Of Vascular Training And Training Programs: Current Status Of The 0.5 Programs And Number Of Vascular Surgery Applicants And Spots
Karl A. Illig, MD

How To Redesign Workflow To Improve Patient Care And Resident Training
Richard J. Powell, MD

Advantages Of Case Specific Simulator Rehearsal With Endovascular Procedures
Isabelle Van Herzeele, MD, PhD

What’s New And Better With The Pontresina Vascular Surgery Simulator Course For Trainees
Hans-Henning Eckstein, MD, PhD

Guidelines Are Outdated By The Time They Are Published: Some Examples
Janet T. Powell, MD, PhD

Randomized Controlled Trials Can Be Misleading Even When Reported In Leading Journals: Guidelines Based On These Trials Can Also Be Misleading
Frank J. Veith, MD

Cost Per Day Of Patency In Endo vs. Open Lower Extremity Revascularization Procedures
Manish Mehta, MD, MPH
Cost Effectiveness Of Different Treatment Strategies For CLI With Gangrene Or Necrosis
Michael Belkin, MD

Panel Discussion

SESSION 47 (Grand Ballroom East, 3rd Floor)
MORE ABOUT HEALTH CARE REFORM, FDA, ETHICS, COSTS, STANDARDS AND GUIDELINES (5-MINUTE TALKS)
Moderators: Kim J. Hodgson, MD
Thomas F. O’Donnell, Jr., MD

2:00 – 2:05 Impact Of Obamacare On Medicine In The US
Clifford J. Buckley, MD
Shirley Buckley, RN

2:06 – 2:11 Why The Canadian Health Care System Works Better Than Obamacare Will
Dheeraj Rajan, MD

2:12 – 2:17 How Should Aviation Training Serve As A Model For Educating Vascular Surgeons
John F. Eidt, MD

2:18 – 2:23 What Has And Will The FDA Do To Medical Innovation In The US: An FDA Consultant’s Perspective: Will Things Improve
Thomas J. Fogarty, MD

Dorothy B. Abel, BSBME
Kenneth J. Cavanaugh, Jr., PhD

2:30 – 2:35 How To Get A Physician-Sponsored IDE: Tips And Tricks
Benjamin W. Starnes, MD

Jean-Baptiste Ricco, MD, PhD

Jack L. Cronenwett, MD

Scott L. Stevens, MD

2:54 – 3:10 Panel Discussion And Break
Visit Pavilions and Exhibits (2nd and 3rd Floors)

CONCURRENT SATURDAY AFTERNOON PROGRAMS

PROGRAM K (SESSIONS 48 – 49)
3:10 P.M. – 6:10 P.M.
Vascular Disease; Medical Treatment; Complications, New Techniques And Concepts
Grand Ballroom East, 3rd Floor

PROGRAM L (SESSIONS 50 – 51)
3:10 P.M. – 6:10 P.M.
Updates, New Technology And Concepts; More New Concepts, Updates And Techniques
Grand Ballroom West, 3rd Floor
PROGRAM K (SESSIONS 48 – 49)  
(Grand Ballroom East, 3rd Floor)

SESSION 48  
(Grand Ballroom East, 3rd Floor)  
VASCULAR DISEASE NATURAL HISTORY; MEDICAL TREATMENT; PREVENTION AND TREATMENT OF COMPLICATIONS (5-MINUTE TALKS)

Moderators: Vivian Gahtan, MD  
Peter F. Lawrence, MD

3:10 – 3:15  
New Developments In Anticoagulant Drugs For Vascular Patients  
Anthony J. Comerota, MD

3:16 – 3:21  
Decision Making Tool For Determining Which CLI Treatment Is Best: Open vs. Endovascular  
Darren B. Schneider, MD

3:22 – 3:27  
Ongoing Developments In Drug Treatment Of Vascular Disease: Do HDL Raising Drugs Show Promise For Preventing Strokes And MIs  
Ron Waksman, MD

3:28 – 3:33  
Role Of Optimal Medical Treatment In Stroke Prevention: Does It Really Work  
Michael R. Jaff, DO

3:34 – 3:39  
DEBATE: The Truth About Statin Toxicity: Has It Been Overplayed By The FDA And By The Media  
Bruce A. Perler, MD, MBA

3:40 – 3:45  
DEBATE: Statins May Be Harmful And Should Be Used Less  
Sherif Sultan, MD

3:46 – 3:51  
How Should We Interpret The JUPITER Trial Showing The Value Of Statins: Has JUPITER Gotten A Bum Rap  
Russell H. Samson, MD, RVT

3:52 – 3:57  
Do L-Arginine Supplements Help Vascular Patients: When And How Should They Be Given  
Vikram S. Kashyap, MD

3:58 – 4:03  
Carotid Glomectomy Is A Good Treatment For Syncopeal Vasophlegia: How To Do It  
Erik E. Debing, MD, PhD

4:04 – 4:09  
Interactive Telephone Program To Allow Daily Monitoring Of Vascular Patients  
John (Jeb) W. Hallett, MD

4:10 – 4:15  
Comparative Performance Of Rotorex And Angiojet For Clot Removal From Lower Extremity Arteries: Advantages And Limitations Of Each  
Hermann Steinkamp, MD

4:16 – 4:21  
A New Device To Treat Resistant Hypertension By Carotid Baroreceptor Stimulation: The BAROSTIM Trial  
Fred A. Weaver, MD

4:22 – 4:29  
Routine Use Of Ultrasound Guidance And Micropuncture Makes Endovascular Access Safer: How To Do It  
Peter A. Schneider, MD

4:30 – 4:37  
Panel Discussion
SESSION 49 (Grand Ballroom East, 3rd Floor)
NEW TECHNIQUES; NEW CONCEPTS
(5-MINUTE TALKS)
Moderators: Michael B. Silva, Jr., MD
John J. Ricotta, MD

4:38 – 4:43
Is There Still A Place For Unilateral And Even Bilateral Hypogastric Embolization In 2012: How Safe Is It
Dieter Raithel, MD, PhD

4:44 – 4:49
Hypogastric Preservation In Patients With Common Iliac Aneurysms Using Off-The-Shelf Devices
Karthikeshwar Kasirajan, MD

4:50 – 4:55
Unusual Causes Of Upper Extremity Arterial Occlusive Disease
Kenneth J. Cherry, MD

4:56 – 5:01
Catheter Directed Prostaglandins Are An Effective Treatment For CLI: As The Sole Treatment Or As An Adjunct To Other Endovascular Therapy
Oscar L. Ojeda, MD
Marcelo Patero, MD

5:02 – 5:07
Carotid Interventions For Acute Stroke: When Are They Worthwhile And When Are They Not
R. Clement Darling III, MD

5:08 – 5:13
How Do Pericardial Patches Heal And Why Are They Likely To Resist Infection
Alan Dardik, MD, PhD

5:14 – 5:19
Imaging And Endovascular Techniques In The Removal Of Transvenous Pacer And ICD Leads
Ali Khoynezhad, MD, PhD

5:20 – 5:25
Laparoscopic Treatment Of The Arcuate Ligament Syndrome: Technique, Indications And Results
Yves Alimi, MD

5:26 – 5:31
Update On Treatment Of Infected Abdominal And Thoracic Endografts: Is It A Solvable Or Hopeless Problem And Is Non-Excisional Treatment Ever Successful
Peter R. Taylor, MA, MChir

5:32 – 5:37
Non-Atherosclerotic Aortic Thrombosis: Causes, Diagnosis And Treatment
Cynthia K. Shortell, MD

5:38 – 5:43
The SoloPath Expandable Introducer Sheath: How Does It Work And How Can It Be Helpful In EVAR Procedures
Jeffrey P. Carpenter, MD

5:44 – 5:49
Management Of Infected CEA Patches: A 10-Year Experience
Ali F. AbuRahma, MD

5:50 – 5:55
In Situ Fenestration For Left Subclavian Revascularization During TEVAR Is Safer And Better Than Carotid Subclavian Bypass: How To Do It
Frank R. Arko, MD

5:56 – 6:01
Bell Bottom Iliac Limbs Have A Downside
Gustavo S. Oderich, MD

6:02 – 6:10
Panel Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10</td>
<td>Current Optimal Treatment Of Atrial Fibrillation In Vascular Patients</td>
<td>Jeffrey S. Berger, MD, MS</td>
</tr>
<tr>
<td>3:16</td>
<td>Prevalence Of Carotid Stenosis Varies According To Race: Highest In Caucasians And Native Americans</td>
<td>Caron B. Rockman, MD</td>
</tr>
<tr>
<td>3:28</td>
<td>Bioabsorbable Scaffolds (REMEDY Stent), DEBs And DESs, In The SFA: What Is Their Future</td>
<td>Sumaira Macdonald, MBChB, PhD</td>
</tr>
<tr>
<td>3:34</td>
<td>Can The Achilles Tendon Be Excised Safely And With Minimal Disability To Treat Bad Heel Wounds And Plantar Pedal Ulcers</td>
<td>Wayne Caputo, DPM</td>
</tr>
<tr>
<td>3:40</td>
<td>Drug Eluting Balloon Evaluation For Lower Limb Multilevel Treatment – DEBELLUM Trial: 1-Year Results</td>
<td>Fabbriano Fanelli, MD</td>
</tr>
<tr>
<td>3:46</td>
<td>Bypses For Hand Digital Ischemia: What Is Their Role And Their Results</td>
<td>R. Clement Darling III, MD</td>
</tr>
<tr>
<td>3:52</td>
<td>Retrohepatic Balloon Occlusion Of The IVC For Trauma And Renal Cell Cancer: How To Do It With Current Technology</td>
<td>Joseph S. Giglia, MD</td>
</tr>
<tr>
<td>3:58</td>
<td>Carotid-To-Axillary Bypass Is Useful As A Debranching Technique And Easier And Less Risky Than Carotid-To-Subclavian Bypass</td>
<td>Frank J. Criado, MD</td>
</tr>
<tr>
<td>4:04</td>
<td>VIATORR Covered Stent For Early TIPS And Its Effect On Hepatic Encephalopathy And Ascites: Other New Horizons In TIPS</td>
<td>Ziv J. Haskal, MD</td>
</tr>
<tr>
<td>4:10</td>
<td>Which Post EVAR Patients Need Minimal Follow-up Surveillance: What Should That Consist Of</td>
<td>Hence J.M. Verhagen, MD, PhD</td>
</tr>
<tr>
<td>4:16</td>
<td>Angioslide Angioplasty Balloon With Embolic Capture (Proteus Device): When To Use It And Evidence Of Effectiveness</td>
<td>Peter C.J. Goverde, MD</td>
</tr>
<tr>
<td>4:22</td>
<td>Outcomes Of Endovascular Treatment Of Lower Extremity Lesions Are Worse In Young Patients (&lt;50)</td>
<td>Rabih A. Chaer, MD</td>
</tr>
<tr>
<td>4:28</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>
SESSION 51 (Grand Ballroom West, 3rd Floor)
MORE NEW CONCEPTS, UPDATES AND NEW TECHNIQUES (5-MINUTE TALKS)

Moderators: Enrico Ascher, MD
Palma M. Shaw, MD

4:34 – 4:39
Limitations Of A Large Palmaz Stent For Treating Type I Endoleaks
Tilo Koelbel, MD, PhD

4:40 – 4:45
Recent Volumetric Analyses Of Post EVAR AAA Sac Behavior: Is Sac Enlargement Still A Concern
Mark F. Fillinger, MD

4:46 – 4:51
2-Stage Treatment For Aorto-Enteric Fistulas
Gioacchino Coppi, MD

4:52 – 4:57
Siena Score For Evaluating AAAs Suitability For EVAR: What Is It And How Does It Help
Francesco Setacci, MD

4:58 – 5:03
Advantages And Early Results Of The ALTURA Ultra Low Profile AAA Endograft
Albrecht H. Krämer, MD

5:04 – 5:09
Fascial Sutute To Close Large Percutaneous Sheath Insertion Sites Cheaply And Effectively (The Larzon Technique): Tips And Tricks
Timothy A. Resch, MD, PhD

5:10 – 5:15
Advantages And Limitations Of The Ovation Endograft (TriVascular) For AAA Repair: Based On The 1-Year Global Experience
Manish Mehta, MD, MPH

5:16 – 5:21
Current Status Of Silver Impregnated Grafts To Treat Aortic Infection: Are We In The US Being Denied A Valuable Treatment Adjunct
Max Zegelman, MD, PhD

5:22 – 5:27
Antibiotic Drug Delivery Implants Facilitates Treatment Of Some Infected Vascular Prosthetic Grafts
Dennis F. Bandyk, MD

5:28 – 5:33
DW-MRI Based Evidence That Interruption Of Flow Embolic Protection With The MoMa Device Is Effective During CAS (The DESERVE Trial)
Giancarlo Biamino, MD, PhD

5:34 – 5:39
Optimal Current Use Of Anticoagulants And Antiplatelet Drugs In Patients Undergoing CEA
Timothy M. Sullivan, MD

5:40 – 5:45
Causes And Implications Of 30-Day Readmissions After AAA Repair: Endo And Open
K. Craig Kent, MD

5:46 – 5:51
BASIL Survival Prediction Model In Patients With CLI: Validation And Comparison With PREVENT And FINNUVASC Scores
Robert J. Hinchliffe, MD

5:52 – 5:57
Importance Of Pressure Gradients In Assessing Hemodynamic Significant Vascular Lesions: A Simple Method To Measure Them
Ali Amin, MD, RVT

5:58 – 6:05
Panel Discussion
SESSION 52  (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS AND UPDATES: EARLY CAROTID TREATMENT, TAKAYASU’S DISEASE AND TECHNIQUES FOR EVALUATING CAROTID PLAQUES NONINVASIVELY (5-MINUTE TALKS)
Moderators: Frans L. Moll, MD, PhD
Lucien D. Castellani, MD

6:40 – 6:45 Techniques For Crossing Over Difficult Aortic Bifurcations To Deliver Contralateral Interventions
Scott L. Stevens, MD

6:46 – 6:51 Outcomes Of Urgent CEA In Symptomatic Patients: Are They Acceptable
Gabriel Szendro, MD

6:52 – 6:57 Can The 14-Day Treatment Target For Symptomatic Carotid Disease Patients Be Met: Are The Outcomes Acceptable
A. Ross Naylor, MD

6:58 – 7:03 Results Of Urgent CEA In Symptomatic Patients: Can CAS Results Equal Them
Laura Capoccia, MD, PhD

7:04 – 7:09 Is Early Intervention For Symptomatic Carotid Stenosis As Good For CAS As CEA
Sumaira Macdonald, MBChB, PhD

7:10 – 7:15 How To Treat Cerebral Ischemia From Takayasu’s Disease
Zhong Gao Wang, MD

7:16 – 7:21 When Is Endovascular Treatment Of Takayasu’s With PTA, Stent Or Stent-Graft Indicated And Justified By The Results
Xiaoyun Luo, MD

7:22 – 7:27 Pros And Cons Of Open Bypass Surgery And Endovascular Procedures With Supra-aortic Lesions Due To Takayasu’s Disease
Young Wook Kim, MD

7:28 – 7:33 Panel Discussion
Moderators: Thomas S. Riles, MD
Allan L. Brook, MD

7:34 – 7:38 DEBATE: Key Findings In The SAMMPRIS Trial Showing Intracranial Stents To Be Less Effective Than Best Medical Treatment In Preventing Strokes
Colin P. Derdeyn, MD

7:40 – 7:45 DEBATE: SAMMPRIS Had Major Flaws And Reached Misleading Conclusions
L. Nelson Hopkins, MD

7:46 – 7:51 How To Make Endovascular Treatment Of Acute Strokes Work Best In 2012: Why Have Some Of The Trials To Date Been Negative
Don Frei, MD

7:52 – 7:57 Relationship Between IVUS-Characterized Plaque Morphology And Embolic Potential – Spontaneously And During CAS
Wei Zhou, MD
Dynamic Contrast Ultrasonography To Stratify Risk In Asymptomatic Carotid Stenosis Patients: How Does It Work
Alan H. Davies, MA, DM

3-D Ultrasound And MRI Assessment Of Carotid Plaques: Do Statins Result In Plaque Shrinkage And Other Beneficial Changes
Henrik Sillesen, MD, DMSc

How To Identify Asymptomatic Carotid Stenoses At High Risk For Causing A Stroke: Searching For The Holy Grail
Jose Fernandes e Fernandes, MD, PhD

Impact Of Contralateral Carotid Occlusion (CCO) On The Comparative Results Of CEA And CAS For Treatment Of Carotid Stenosis: CAS Is Equivalent To CEA With CCO
Joseph J. Ricotta II, MD, MS
Gilbert R. Upchurch, MD
Gregg S. Landis, MD

Panel Discussion

Current Treatment Of Para-Anastomotic Aneurysms After Open Surgery: They Are Easily Fixed Endovascularly
Arno von Ristow, MD

Endovascular Treatment Of Late Complications From Open AAA Surgery
Giancarlo Mansueto, MD

MRI Is Better Than CTA For Finding Endoleaks And Identifying Their Type: Why
Frans L. Moll, MD, PhD

EVAR Of Primary Infected (Mycotic) AAAs: Results Are Surprisingly Good But Not Universally So
Anders Vanhainen, MD, PhD
Martin Björck, MD, PhD

Techniques For Safe Open Conversion After Failed EVAR And TEVAR
Germano Melissano, MD
Roberto Chiesa, MD

Complications Of TEVAR For Treatment Of Traumatic Aortic Injury And How They Can Be Prevented And Treated
Ali Azizzadeh, MD

How To Treat AAAs With <14 mm Distal Necks Safely With Bifurcated Endografts
Gustavo S. Oderich, MD

Cost Effectiveness Of EVAR And Open Repair In The OVER Trial After 2 Years
Frank A. Lederle, MD

Thoracic Aortic Aneurysm In Patients With AAAs: How Common Are They And When Should They Be Looked For With Chest CT
Rabih A. Chaer, MD
Michel S. Makaroun, MD
SESSION 54 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN CAROTID DISEASE TREATMENT AND ASSOCIATED ISSUES (5-MINUTE TALKS)

Moderators: Hans-Henning Eckstein, MD, PhD
John B. Chang, MD

10:00 – 10:05 Current Stent Design For CAS Procedures Is Inadequate: What Is On The Horizon To Remedy This Sumaira Macdonald, MBChB, PhD


10:12 – 10:17 CAS Or CEA For Carotid Disease Associated With Neck Radiation: Which Treatment Is Best Frans L. Moll, MD, PhD

10:18 – 10:23 Value And Limitation Of Optical Coherence Tomography To Evaluate Carotid Plaques And Luminal Anatomy Before And After CAS Carlo Setacci, MD

10:24 – 10:29 Simplified Safe Technique For Carotid Subclavian Bypass Ramon Berguer, MD, PhD Mark D. Morasch, MD

10:30 – 10:35 DEBATE: When Should A Shunt Be Used During CEA: From the VSGNE Philip P. Goodney, MD, MS Jack L. Cronenwett, MD

10:36 – 10:41 DEBATE: A Shunt Should Never Be Used During CEA: What Is Required To Use The No-Shunt Technique Safely Russell H. Samson, MD, RVT

10:42 – 10:47 Panel Discussion

Moderators: Daniel G. Clair, MD Thomas S. Riles, MD

10:48 – 10:53 Technical Tricks And Devices Make CAS Easier And Safer With The MoMa Flow Cessation Device And The 2 Wire PITON Catheter Gioacchino Coppi, MD

10:54 – 10:59 Predictors Of Early Adverse Outcomes After CEA: Are They An Indication For CAS Erik E. Debing, MD, PhD

SESSION 54 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN CAROTID DISEASE TREATMENT AND ASSOCIATED ISSUES (5-MINUTE TALKS)

Moderators: Hans-Henning Eckstein, MD, PhD
John B. Chang, MD

10:00 – 10:05 Current Stent Design For CAS Procedures Is Inadequate: What Is On The Horizon To Remedy This Sumaira Macdonald, MBChB, PhD


10:12 – 10:17 CAS Or CEA For Carotid Disease Associated With Neck Radiation: Which Treatment Is Best Frans L. Moll, MD, PhD

10:18 – 10:23 Value And Limitation Of Optical Coherence Tomography To Evaluate Carotid Plaques And Luminal Anatomy Before And After CAS Carlo Setacci, MD

10:24 – 10:29 Simplified Safe Technique For Carotid Subclavian Bypass Ramon Berguer, MD, PhD Mark D. Morasch, MD

10:30 – 10:35 DEBATE: When Should A Shunt Be Used During CEA: From the VSGNE Philip P. Goodney, MD, MS Jack L. Cronenwett, MD

10:36 – 10:41 DEBATE: A Shunt Should Never Be Used During CEA: What Is Required To Use The No-Shunt Technique Safely Russell H. Samson, MD, RVT

10:42 – 10:47 Panel Discussion

Moderators: Daniel G. Clair, MD Thomas S. Riles, MD

10:48 – 10:53 Technical Tricks And Devices Make CAS Easier And Safer With The MoMa Flow Cessation Device And The 2 Wire PITON Catheter Gioacchino Coppi, MD

10:54 – 10:59 Predictors Of Early Adverse Outcomes After CEA: Are They An Indication For CAS Erik E. Debing, MD, PhD
The Case Against Routine Carotid Patching Despite All The Level I Evidence And Hype: How And When To Avoid Patches
Glen M. LaMuraglia, MD

Endovascular Treatment And Bailout Of Complications From Carotid Surgery: A Simpler Better Solution Than Redo Surgery
Giovanni P. Deriu, MD

A New Better Monitoring Technique For CEA: Light General/Endotracheal Anesthesia Which Allows Patients To Demonstrate Motor Function: It Really Works And Decreases Patient And Surgeon Stress
Giancarlo G.C. Accarino, MD

PTFE Interposition Grafts For CEA Gone Wrong: An Effective And Durable Bailout Procedure
Dieter Raithel, MD, PhD

DEBATE: AHA And European Cardiology Guidelines For CAS Have It Right: CAS Is An Alternative To CEA For Symptomatic Patients With Carotid Stenosis
Alberto Cremonesi, MD

DEBATE: Nonsense: The SVS Guidelines Have It Right: CAS Is Not An Alternative To CEA For Most Symptomatic Patients With Carotid Stenosis
Michel S. Makaroun, MD

Comparison Of 5 Different Guidelines For Treating Carotid Stenosis: How Can Such Differing Interpretations Be Drawn From The Same Data
Kosmas I. Paraskevas, MD Dimitri P. Mikhailidis, MD Frank J. Veith, MD

CREST Cost Comparisons Between CAS And CEA: Possible Flaws In The CREST Cost Data That Make Its Conclusions Misleading
W. Charles Sternbergh III, MD

Impact Of Cranial Nerve Defects (CRI) In CREST At One Year: These CRIs Were Minor And Not Equivalent To Strokes
Thomas G. Brott, MD

DEBATE: CEA vs. CAS In Symptomatic Patients: The Heart Should Not Rule The Head When Deciding Treatment Strategies
A. Ross Naylor, MD

DEBATE: CEA vs. CAS In Symptomatic Patients: The Heart Should Rule The Head When Deciding Treatment Strategies
Peter A. Schneider, MD

Which Carotid Patients Needing Invasive Treatment Do I Currently Send For CEA
Klaus D. Mathias, MD

Are CAS vs. CEA Trials Inherently Biased: Critical Appraisal Of Endpoints
Timothy M. Sullivan, MD
DEBATE: Many Selected Asymptomatic Carotid Stenosis Patients Benefit From CEA: How Should They Be Picked
Bruce A. Perler, MD, MBA

DEBATE: Not So: With Asymptomatic Carotid Stenosis Patients Any Benefit Of Invasive Treatment Is Outweighed By The Risks
Anne L. Abbott, MD, PhD

How To Risk Adjust Symptomatic And Asymptomatic Patients For CAS And CEA: A View Of A Vascular Specialist Who Does Both
Jon S. Matsuzaka, MD

Current Strategies For Treating Carotid And Vertebral Dissections
L. Nelson Hopkins, MD

Is A Postop MI With Only A Rise In Troponin A Bad Thing And Predictive Of Late Increased Mortality Risk
Andres Schanzer, MD

A Postop MI With Only A Rise In Troponin Is A Bad Thing But No Worse A Predictor Of Late Mortality Than Any Stroke: Based On CREST And Other Data
Wesley S. Moore, MD

Panel Discussion
Lunch available in the Grand Ballroom.

SESSION 56 (Grand Ballroom East, 3rd Floor)
NEW HORIZONS, NEW CONCEPTS AND LATE BREAKING DEVELOPMENTS (5-MINUTE TALKS)
Moderators: John E. Connolly, MD
Enrico Ascher, MD

Technique Of Balloon Common Iliac Occlusion To Facilitate Antegrade Wire Passage Through Flush Iliac Occlusions: A Cheaper Safer Way
Peter H. Lin, MD

Proportion Of CLI Patients Requiring Open Surgery When Endo Is The First And Favored Option: A Totally Endo First Strategy May Not Be Cost Effective
Firas F. Mossa, MD

What Happens When SFA And Popliteal Stents Fail
Steven G. Katz, MD

CFA Stenting Can Be Done Safely And Effectively In An Outpatient Setting: Tips And Tricks
Sam S. Ahn, MD, MBA

Results Of The DUET Trial: A RCT Comparing Ultrasound Enhanced vs. Standard Thrombolysis For Arterial Occlusions
Jean-Paul de Vries, MD, PhD

Xenograft Pericardial Tubes And Radical Debridement Of Surrounding Tissues: A New Concept For Treating Prosthetic Graft Infections
Jürg Schmidli, MD

Current Optimal Treatment Of Carotid And Vertebral Spontaneous And Traumatic Dissections
Irwin V. Mohan, MD

Laser Atherectomy: Will It Make A Comeback In CLI Treatment
Grayson H. Wheatley, MD
Update On The SETA Balloon Expandable AAA Endograft: Mid-Term Clinical Experience
Hernan G. Bertoni, MD

Panel Discussion
Moderators: James F. McKinsey, MD Lucien D. Castellani, MD

Open Aortic Repair After Failed EVAR: Tips And Tricks To Lower Morbidity And Mortality
R. Clement Darling III, MD

Crossing Lower Extremity CTOs Using The VIANCE AND ENTER Devices: Final Results Of The PFAST Trial
Subhash Banerjee, MD

Endovascular Techniques For Carotid And Cerebral Artery Thrombectomy For Acute Stroke: Experience In >130 Patients
Klaus D. Mathias, MD

Interventions Performed Within 1 Week Of A Neurological Event: Outcomes Of CEA Are Better Than CAS (Data From The EVA-3S, The SPACE And The ICSS Trials)
Gustav Fraedrich, MD Barbara Rantner, MD Georg Goebel, MD and Leo H. Bonati, MD
On behalf of the CSTC

How Was CREST Data Presented In The FDA Application For Low Risk Carotid Stenting In A Way That Renders Them Misleading
Thomas G. Brott, MD

Filters vs. Flow Reversal And Occlusion: Advantages And Disadvantages Of Both
Claudio J. Schonholz, MD

SVS Registry Results Show CEA To Have Superior Outcomes To Those Of CAS In Symptomatic And Asymptomatic Patients Over 65
Brian G. Rubin, MD

Endovascular Conversion Of Open Surgical Failures And Complications: Tips And Tricks
Jos C. van den Berg, MD, PhD

Can Medical Treatments Decrease AAA Growth Rates: Prospects For The Future
Russell H. Samson, MD, RVT

Panel Discussion

SESSION 57 (Grand Ballroom East, 3rd Floor)
LATE BREAKING TOPICS OF PARTICULAR INTEREST (5-MINUTE TALKS)
Moderators: Kenneth Ouriel, MD, MBA Frank J. Veith, MD

Comparative Outcomes Of Bell Bottom Technique And Hypogastric Exclusion For Common Iliac Aneurysms Treated By EVAR: Bell Bottom Wins
Mark K. Eskandari, MD

4-Year Results With Sandwich Technique For Treating Common And Internal Iliac Aneurysms
Armando C. Lobato, MD, PhD

Iliac Branched Devices Work Well In Worldwide Experience: The PRESERVE Trial
W. Anthony Lee, MD
Infected AAAs: Endovascular Therapy Should Be The First Choice: How To Make It Work With 2-6 Years Follow-up
Boonprasit Kritpracha, MD

Novel Technique For Treating Type II Endoleaks By Accessing AAA Sac And Nidus Via Distal Endograft Attachment Site
Giocchino Coppi, MD

Flow Control To Prevent Embolic Complications During Endovascular Treatment Of Aortoiliac Occlusive Disease
Claudio I. Schonholz, MD

Treatment Of Refractory Postthrombotic Syndrome By Cutting Balloon Angioplasty Of The Popliteal Vein
Thomas O. McNamara, MD

Prevention Of Restenosis After PTA By A Device (Mercator) To Inject Periadventitial Tissue With Dexamethasone
Patrice F. Bergeron, MD
Jean-Pierre Becquemin, MD

Military Translational Research To Develop A New Fluoroscopy-Free Endovascular Balloon Occlusion System To Treat End-Stage Shock
Todd E. Rasmussen, MD

Double Chimney Technique To Treat Arch Aneurysms: How To Make Them Work
Jan S. Brunkwall, MD, PhD

Endovascular Graft Treatment Of Popliteal Aneurysms Is As Effective As Open Surgery In Terms Of Long-Term Patency
Michel S. Makaroun, MD
Rabih A. Chaer, MD

Panel Discussion

Raffle Drawing – You Must Be Present To Win

Symposium Ends

Save The Date: November 20-24, 2013
Hilton New York
6 - 9 APRIL 2013
REGISTER NOW
NATIONAL HALL, OLYMPIA
LONDON, UK
WWW.CXSYMPOSIUM.COM

EDUCATION
INNOVATION
EVIDENCE
VASCULAR & ENDOVASCULAR
CHALLENGES UPDATE
Incorporating
ADVANCED IMAGING FOR INTERVENTIONS

Download the CX App
www.bibamedical.com/apps

twitter
To join the conversation search
@cxsymposium on twitter

Follow CX Symposium
on facebook

email: info@cxsymposium.com
symposium hotline: +44 (0) 20 7736 8788
fax: +44 (0) 20 7736 8283
FACULTY

Anne L. Abbott, MD, PhD, FRACP, FRACGP
Melbourne, Australia

Dorothy B. Abel, BSME
Silver Spring, Maryland

Apollonia E. Abramowicz, MD
Bronx, New York

Kenneth D. Abreo, MD
Shreveport, Louisiana

Ali F. AbuRahma, MD
Charleston, West Virginia

Giancarlo G.C. Accarino, MD
Salerno, Italy

Charles W. Acher, MD
Madison, Wisconsin

Mark A. Adelman, MD
New York, New York

Sam S. Ahn, MD, MBA, FACS
Los Angeles, California and Dallas, Texas

Afsaneh Alavi, MD, FRCPC
Toronto, Canada

Yves Alimi, MD
Marseille, France

Jose I. Almeida, MD, RVT, FACS
Miami, Florida

Ali Amin, MD, RVT, FACS, FACC
Reading, Pennsylvania

Max Amor, MD
Essey-Lès-Nancy, France

Gary M. Ansel, MD
Columbus, Ohio

Frank R. Arko, MD
Charlotte, North Carolina

John E. Aruny, MD
New Haven, Connecticut

Enrico Ascher, MD
Brooklyn, New York

Afshin Assadian, MD
Vienna, Austria

Ali Azizzadeh, MD
Houston, Texas

Nobuyoshi Azuma, MD
Asahikawa, Hokkaido, Japan

Martin R. Back, MD
Tampa, Florida

Jörn O. Balzer, MD, PhD
Mainz, Germany

Dennis F. Bandyk, MD
La Jolla, California

Subhash Banerjee, MD
Dallas, Texas

Richard A. Baum, MD, MPA, MBA
Boston, Massachusetts

Jonathan D. Beard, MD
Sheffield, United Kingdom

Jean-Pierre Becquemin, MD, FRCS
Cretel, France

Michael Belkin, MD
Boston, Massachusetts

Amira Benjelloun, MD
Rabat, Morocco

Jeffrey S. Berger, MD, MS, FAHA, FACC
New York, New York

Patrice F. Bergeron, MD
Marseille, France

Ramon Berguer, MD, PhD
Ann Arbor, Michigan

Todd Berland, MD
New York, New York

Hernan G. Bertoni, MD
Buenos Aires, Argentina

Giancarlo Biamino, MD, PhD
Mergoiano (AV), Italy

Giorgio M. Biasi, MD
Milan, Italy

Jean Bismuth, MD
Houston, Texas

James H. Black III, MD
Baltimore, Maryland

Jan D. Blankenstein, MD
Amsterdam, The Netherlands

John Blebea, MD, MBA
Tulsa, Oklahoma

Dittmar Boeckler, MD
Heidelberg, Germany

Thomas Boeni, MD
Zurich, Switzerland

Amman Bolia, MD
Leicester, United Kingdom

Marc Bosiers, MD
Dendermonde, Belgium

Bruce J. Brenner, MD
Livingston and Newark, New Jersey

Marc A. Brenner, DPM
Glendale and Manhasset, New York

Fleur E. Brolmann, MD
Amsterdam, The Netherlands

Allan L. Brook, MD
Bronx, New York

Thomas G. Brott, MD
Jacksonville, Florida

O. William Brown, MD, JD
Royal Oak, Michigan

Elchanan Bruckheimer, MBBS
Petah-Tikva, Israel

Jan S. Brunkwall, MD, PhD
Cologne, Germany

Clifford J. Buckley, MD
Temple, Texas

Nick J. Burrill, BSc, MB, BCHir, MRCS, FRCR
London, United Kingdom

Ronald G. Bush, MD
Dayton, Ohio

Jacques Busquet, MD
Paris, France

Keith D. Calligaro, MD
Philadelphia, Pennsylvania

Richard P. Cambria, MD
Boston, Massachusetts

Piergiorgi Cao, MD, FRCS
Rome, Italy

Lou Caplan, MD
Boston, Massachusetts

Laura Capoccia, MD, PhD
Rome, Italy

Wayne Caputo, DPM
Belleville, New Jersey and New York, New York

Jeffrey P. Carpenter, MD
Carmel, New Jersey

Lucien D. Castellani, MD
Tours, France
Neal S. Cayne, MD
New York, New York
Rabih A. Claer, MD
Pittsburgh, Pennsylvania
Elliot L. Chaikof, MD, PhD
Boston, Massachusetts
John B. Chang, MD
Roslyn, New York
Stephen W.K. Cheng, MBBS
Hong Kong, China
Zhuo Cheng, PhD
London, United Kingdom
Kenneth J. Cherry, MD
Charlottesville, Virginia
Nicholas J.W. Cheshire, MD
London, United Kingdom
Roberto Chiesa, MD
Milano, Italy
Marc Chimowitz, MD
Charleston, South Carolina
Larry Chinitz, MD
New York, New York
Kyung Cho, MD
Ann Arbor, Michigan
Timothy A.M. Chuter, DM
San Francisco, California
Daniel G. Clair, MD
Cleveland, Ohio
Giacomo Clerici, MD
Milan, Italy
Rachel Clough, MD, PhD
London, United Kingdom
Anthony J. Comerota, MD, FACS, FACC
Toledo, Ohio
John E. Connolly, MD
Orange, California
Mark Conrad, MD
Boston, Massachusetts
Michael S. Conte, MD
San Francisco, California
Gioacchino Coppi, MD
Modena, Italy
Joseph S. Coselli, MD
Houston, Texas
Robert Craig, DO
Bethesda, Maryland
Alberto Cremonesi, MD, FESC
Cottignola, Italy
Enrique Criado, MD, FACS
Ann Arbor, Michigan
Frank J. Criado, MD, FACS, FSVM
Baltimore, Maryland
Jack L. Cronenwett, MD
Lebanon, New Hampshire
David L. Cull, MD, FACS
Greenville, South Carolina
Jacob Cynamon, MD
New York, New York

R. Clement Darling III, MD
Albany, New York
Tony S. Das, MD
Dallas, Texas
Alun H. Davies, MA, DM, FRCS, FHEA, FEBVS, FACP
London, United Kingdom
Jean-Paul de Vries, MD, PhD
Nieuwegein, The Netherlands
David H. DePalma, MD
Washington, District of Columbia
Erik E. Debing, MD, PhD
Brussels, Belgium
Sebastian E. Debus, MD, PhD
Hamburg, Germany
Koen Deloose, MD
Dendermonde, Belgium
Ralph G. DePalma, MD
Washington, District of Columbia
Colin P. Derdeyn, MD
St. Louis, Missouri
Giovanni P. Deriu, MD
Padova, Italy
Florian Dick, MD
Bern, Switzerland
Nicolas A. Diehm, MD
Bern, Switzerland
Edward B. Dietrich, MD
Phoenix, Arizona
Alan M. Dietzek, MD, RPVI, FACS
Danbury, Connecticut
Aaron S. Dumont, MD
Philadelphia, Pennsylvania

Hans-Henning Eckstein, MD, PhD
Münich, Germany
Michael E. Edmonds, MD
London, United Kingdom
John F. Eidt, MD
Little Rock, Arkansas
Bo G. Eklof, MD, PhD
Helsingborg, Sweden
Steve Elias, MD
New York, New York
Ted C. Engelhardt, MD
New Orleans, Louisiana
Mark K. Eskandari, MD
Chicago, Illinois
Anne M. Eskes, RN, MSc
Amsterdam, The Netherlands

Ronald M. Fairman, MD
Philadelphia, Pennsylvania
Fabrizio Fanelli, MD
Rome, Italy
Mark A. Faber, MD
Chapel Hill, North Carolina
Peter L. Faries, MD, FACS
New York, New York
Ted Feldman, MD
Evanston, Illinois
Jose Fernandes e Fernandes, MD, PhD, FRCS (Eng), FACS
Lisbon, Portugal
Hector Ferral, MD
Chicago, Illinois
Roberto Ferrari, MD
Milan, Italy
Lowell S. Kabnick, MD, FACS, FACPh
New York, New York
Chung-Dann Kan, PhD
Taipei, Taiwan
Paul H.L. Kao, MD
Taipei, Taiwan
Christof Karmonik, PhD
Houston, Texas
Vikram S. Kashyap, MD
Cleveland, Ohio
Karthikeshwar Kasirajan, MD
Regensburg, Germany
Konstantinos Katsanos, MSC, MD, PhD, EBIR
Patras, Greece
Steven G. Katz, MD
Pasadena, California
Barry T. Katzen, MD
Miami, Florida
K. Craig Kent, MD
Madison, Wisconsin
Ali Khoynezhad, MD, PhD
Los Angeles, California
Young Wook Kim, MD
Seoul, Korea
Ted King, MD
Oakbrook Terrace, Illinois
Tilo Koelbel, MD, PhD
Hamburg, Germany
Raghu Kolluri, MD
Springfield, Illinois
Ralf R. Kolvenbach, MD
Duesseldorf, Germany
Dietmar H. Koschyk, MD
Hamburg, Germany
Zvonimir Krajcer, MD, FACC
Houston, Texas
Albrecht H. Krämer, MD
Santiago, Chile
Boonprasit Kritpracha, MD
Hat Yai, Songkhla, Thailand
Nils Kucher, MD
Bern, Switzerland
Toru Kuratani, MD, PhD
Osaka, Japan
Christopher J. Kwolek, MD
Boston, Massachusetts
Gregg S. Landis, MD
Queens, New York
Werner Lang, MD
Erlangen, Germany
David J. Langer, MD
Manhasset, New York
Kamphol Laohapensang, MD
Chiang Mai, Thailand
Thomas Larzon, MD
Örebro, Sweden
Peter F. Lawrence, MD
Los Angeles, California
Frank A. Lederle, MD
Minneapolis, Minnesota
Byung-Boong Lee, MD
Washington, District of Columbia
Jason T. Lee, MD
Stanford, California
Timmy Lee, MD, MSPH, FACRP, FASN
Cincinnati, Ohio
W. Anthony Lee, MD
Boca Raton, Florida
Martin B. Leon, MD
New York, New York
Oleg Leontiev, MD
Philadelphia, Pennsylvania
Mauri J.A. Lepantalo, MD
Helsinki, Finland
Christos D. Liapis, MD
Athens, Greece
David S. Liebeskind, MD
Los Angeles, California
Timothy K. Liem, MD
Portland, Oregon
Francesco Liistro, MD
Arezzo, Italy
Peter H. Lin, MD
Houston, Texas
Jes S. Lindholt, MD
Odense, Denmark
Evan C. Lipsitz, MD
New York, New York
Armando C. Lobato, MD, PhD
Sao Paulo, Brazil
Ian Loftus, MD
London, United Kingdom
Joann Lohr, MD
Cincinnati, Ohio
Charmaine Lok, MD
Toronto, Canada
Joseph V. Lombardi, MD
Camden, New Jersey
Lars Lonn, MD, PhD
Copenhagen, Denmark
Robert A. Lookstein, MD, FSIR, FAHA
New York, New York
Qingsheng Lu, MD
Shanghai, China
Marzia Lugli, MD
Modena, Italy
Alan B. Lumsden, MD, FACS
Houston, Texas
Xiaoyun Luo, MD
Beijing, People’s Republic of China
Fedor Lurie, MD, PhD
Honolulu, Hawaii

Daniel L. Labovitz, MD
New York, New York
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT
Stony Brook, New York
Mario Lachat, MD
Zurich, Switzerland
John R. Laird, MD
Sacramento, California
Brian LaMendola, RN, MBA
Pittsburgh, Pennsylvania
Johannes Lammer, MD
Vienna, Austria
Patrick J. Lamparello, MD
New York, New York
Glenn M. LaMuraglia, MD
Boston, Massachusetts

Werner Lang, MD
Erlangen, Germany
David J. Langer, MD
Manhasset, New York
Kamphol Laohapensang, MD
Chiang Mai, Thailand
Thomas Larzon, MD
Örebro, Sweden
Peter F. Lawrence, MD
Los Angeles, California
Frank A. Lederle, MD
Minneapolis, Minnesota
Byung-Boong Lee, MD
Washington, District of Columbia
Jason T. Lee, MD
Stanford, California
Timmy Lee, MD, MSPH, FACRP, FASN
Cincinnati, Ohio
W. Anthony Lee, MD
Boca Raton, Florida
Martin B. Leon, MD
New York, New York
Oleg Leontiev, MD
Philadelphia, Pennsylvania
Mauri J.A. Lepantalo, MD
Helsinki, Finland
Christos D. Liapis, MD
Athens, Greece
David S. Liebeskind, MD
Los Angeles, California
Timothy K. Liem, MD
Portland, Oregon
Francesco Liistro, MD
Arezzo, Italy
Peter H. Lin, MD
Houston, Texas
Jes S. Lindholt, MD
Odense, Denmark
Evan C. Lipsitz, MD
New York, New York
Armando C. Lobato, MD, PhD
Sao Paulo, Brazil
Ian Loftus, MD
London, United Kingdom
Joann Lohr, MD
Cincinnati, Ohio
Charmaine Lok, MD
Toronto, Canada
Joseph V. Lombardi, MD
Camden, New Jersey
Lars Lonn, MD, PhD
Copenhagen, Denmark
Robert A. Lookstein, MD, FSIR, FAHA
New York, New York
Qingsheng Lu, MD
Shanghai, China
Marzia Lugli, MD
Modena, Italy
Alan B. Lumsden, MD, FACS
Houston, Texas
Xiaoyun Luo, MD
Beijing, People’s Republic of China
Fedor Lurie, MD, PhD
Honolulu, Hawaii

K
FACULTY

Bruce A. Perler, MD, MBA
Baltimore, Maryland

Ivo Petrov, MD, PhD
Sofia, Bulgaria

Timothy A. Pfle德er, MD
Peoria, Illinois

Paul Pittaluga, MD
Nice, France

Don Poldermans, MD
Spijkenisse, The Netherlands

Janet T. Powell, MD, PhD
London, United Kingdom

Richard J. Powell, MD
Lebanon, New Hampshire

Bruce A. Perler, MD, MBA
Baltimore, Maryland

Ivo Petrov, MD, PhD
Sofia, Bulgaria

Timothy A. Pfle德er, MD
Peoria, Illinois

Paul Pittaluga, MD
Nice, France

Don Poldermans, MD
Spijkenisse, The Netherlands

Janet T. Powell, MD, PhD
London, United Kingdom

Richard J. Powell, MD
Lebanon, New Hampshire

David Rosenthal, MD
Atlanta, Georgia

Plinio Rossi, MD
Rome, Italy

Howard A. Rowley, MD
Madison, Wisconsin

Prabir Roy-Chaudhury, MD, PhD
Cincinnati, Ohio

Brian G. Rubin, MD
St. Louis, Missouri

Steven H. Rudolph, MD
Brooklyn, New York

Maria Antonella Rufino, MD
Toroio, Italy

Joseph D. Raffetto, MD
West Roxbury, Massachusetts

Dieter Raithel, MD, PhD
Nuremberg, Germany

Dheeraj Rajan, MD, FRCP
Toronto, Canada

Seshadri Raju, MD
Flower, Missouri

Zoran Rancic, MD, PhD
Zurich, Switzerland

Hisham Rashid, MSc, FRCS, FRCS(Orth)
London, United Kingdom

Todd E. Rasmussen, MD, FACS
Fort Sam Houston (San Antonio), Texas

Allan W. Reid, FRCS
Glasgow, United Kingdom

Michel M.P. Reijnen, MD, PhD
Arnhem, The Netherlands

Vincenzo Rambau, MD, PhD
Barcelona, Spain

Jean-Baptiste Racine, MD, PhD
Poitiers, France

Norman M. Rich, MD, FACS, DMCC
Bethesda, Maryland

Götz M. Richter, MD, PhD
Stuttgart, Germany

John J. Ricotta, MD
Washington, District of Columbia

Joseph J. Ricotta II, MD, MS
Atlanta, Georgia

Thomas S. Riles, MD
New York, New York

Krishna J. Rocha-Singh, MD
Springfield, Illinois

Caron B. Rockman, MD
New York, New York

Sean P. Roddy, MD
Albany, New York

Julio A. Rodriguez-Lopez, MD
Phoenix, Arizona

Marco Romanelli, MD, PhD
Pisa, Italy

Sonia Ronchey, MD
Rome, Italy

Eric E. Roselli, MD
Cleveland, Ohio

Kenneth Rosenfeld, MD
Boston, Massachusetts

David Rosenthal, MD
Atlanta, Georgia

Plinio Rossi, MD
Rome, Italy

Howard A. Rowley, MD
Madison, Wisconsin

Prabir Roy-Chaudhury, MD, PhD
Cincinnati, Ohio

Brian G. Rubin, MD
St. Louis, Missouri

Steven H. Rudolph, MD
Brooklyn, New York

Maria Antonella Rufino, MD
Toronto, Italy

Theodore F. Saad, MD
Newark, Delaware

Nirvana Sadaghi-Nejad, MD
Nice, France

Mikel Sadek, MD
New York, New York

Hazed J. Safi, MD
Houston, Texas

Clifford M. Sales, MD, MBA
Summit, New Jersey

Russell H. Samson, MD, RVT, FACS
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

Wilhelm Sandmann, MD
Kamp-Lintfort, Germany

Timur P. Sarac, MD
Cleveland, Ohio

Richard R. Saxon, MD
San Diego, California

Pamela W. Schaefer, MD
Boston, Massachusetts

Andres Schanzer, MD
Worcester, Massachusetts

Dierk Scheinert, MD
Leipzig, Germany

Larry A. Scher, MD
Bronx, New York

Marc L. Schermerhorn, MD
Boston, Massachusetts

A. Frederick Schild, MD
Miami, Florida

Jürg Schmidli, MD
Bern, Switzerland

Andrej Schmidt, MD
Leipzig, Germany

Darren B. Schneider, MD
New York, New York

Peter A. Schneider, MD
Honolulu, Hawaii

Claudio J. Schonholz, MD
Charleston, South Carolina

Geert Willem H. Schurink, MD, PhD
Maastricht, The Netherlands

Louise E. Schwartz, MD
Abbott Park, Illinois

Francesco Serino, MD
Rome, Italy

Carlo Setacci, MD
Siena, Italy

Francesco Setacci, MD
Siena, Italy

Stephen Settle, MD
Austin, Texas

Dhiraj M. Shah, MD
Albany, New York

Theodore F. Saad, MD
Newark, Delaware

Nirvana Sadaghi-Nejad, MD
Nice, France

Mikel Sadek, MD
New York, New York

Hazed J. Safi, MD
Houston, Texas

Clifford M. Sales, MD, MBA
Summit, New Jersey

Russell H. Samson, MD, RVT, FACS
Sarasota, Florida

Luis A. Sanchez, MD
St. Louis, Missouri

Wilhelm Sandmann, MD
Kamp-Lintfort, Germany

Timur P. Sarac, MD
Cleveland, Ohio

Richard R. Saxon, MD
San Diego, California

Pamela W. Schaefer, MD
Boston, Massachusetts

Andres Schanzer, MD
Worcester, Massachusetts

Dierk Scheinert, MD
Leipzig, Germany

Larry A. Scher, MD
Bronx, New York

Marc L. Schermerhorn, MD
Boston, Massachusetts

A. Frederick Schild, MD
Miami, Florida

Jürg Schmidli, MD
Bern, Switzerland

Andrej Schmidt, MD
Leipzig, Germany

Darren B. Schneider, MD
New York, New York

Peter A. Schneider, MD
Honolulu, Hawaii

Claudio J. Schonholz, MD
Charleston, South Carolina

Geert Willem H. Schurink, MD, PhD
Maastricht, The Netherlands

Louise E. Schwartz, MD
Abbott Park, Illinois

Francesco Serino, MD
Rome, Italy

Carlo Setacci, MD
Siena, Italy

Francesco Setacci, MD
Siena, Italy

Stephen Settle, MD
Austin, Texas

Dhiraj M. Shah, MD
Albany, New York
Grayson H. Wheatley, MD
Phoenix, Arizona
Rodney A. White, MD
Los Angeles, California
Mark S. Whiteley, MS, FRCS
Guildford, United Kingdom
Mark H. Wholey, MD
Pittsburgh, Pennsylvania
Chumphon Wilasrusmee, MD, MSc
Bangkok, Thailand
Willem Wisselink, MD
Amsterdam, The Netherlands
Cees H.A. Wittens, MD, PhD
Maastricht, The Netherlands
Edward Y. Woo, MD
Philadelphia, Pennsylvania
Jack Work, MD
Atlanta, Georgia

Osama O. Zaidat, MD
Milwaukee, Wisconsin
Paolo Zamboni, MD
Ferrara, Italy
Christopher K. Zarins, MD
Stanford, California
Clark J. Zeebregts, MD, PhD
Groningen, The Netherlands
Max Zegelman, MD, PhD
Frankfurt, Germany
Thomas Zeller, MD
Bad Krozingen, Germany
Wei Zhou, MD
Stanford, California
Burkhart Zipfel, MD
Berlin, Germany
Gregg H. Zoarski, MD
Newark, Delaware
Robert M. Zwolak, MD, PhD
Lebanon, New Hampshire

Y
Yoshihiko Yokoi, MD
Tokyo, Japan
Albert J. You, MD
Boston, Massachusetts
### Meeting Registration

**Full Registration**

<table>
<thead>
<tr>
<th>Category</th>
<th>Tuition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practicing Physicians</td>
<td>$1395</td>
</tr>
<tr>
<td>Practicing Physicians Combination Rate</td>
<td>$1895</td>
</tr>
<tr>
<td>US and Canadian Vascular Surgery Fellows In Training</td>
<td></td>
</tr>
<tr>
<td>Non-U.S. Fellows</td>
<td></td>
</tr>
<tr>
<td>Physician Assistants</td>
<td>$695</td>
</tr>
<tr>
<td>Residents</td>
<td></td>
</tr>
<tr>
<td>Nurse Practitioners</td>
<td></td>
</tr>
<tr>
<td>Technologists</td>
<td>$650</td>
</tr>
<tr>
<td>Allied Health Care Professionals</td>
<td>$950</td>
</tr>
</tbody>
</table>

*Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc. Letter of verification from Chief of Service must be faxed to 888-418-7043.*

### Component Meetings

- **Wednesday Only - Endovenous Management of Varicose Veins** ... $345
- **Wednesday Only - Hemodialysis Access** ... $345
- **Wednesday Only - WOUNDS** ... $345
- **Wednesday Only - WOUNDS (nurses only)** ... $145
- **Wednesday Only - Emerging Management Options for Pulmonary Embolism** Included in all tuition categories
- **Wednesday Only - Management of Proximal Venous Obstruction** Included in all tuition categories

### Additional Information

**Online:** http://www.VEITHsymposium.org

**Phone:** 800-987-9314, Ext. 200 or 718-549-3140 with your payment information.

**Fax:** the reverse form with your credit card payment to 888-418-7043

**Mail:** this form with your payment to:

The Cleveland Clinic Educational Foundation
Attn: VEITH 020892
P.O. Box 931653
Cleveland, OH 44193-1082

---

**Refund:** There is a $95 cancellation fee if canceled by October 19, 2012. No refunds will be made thereafter.

---

** VEITHsymposium**

4455 Douglas Avenue, Suite 11E
Riverdale, New York 10471

**Phone:** 800-987-9314 or 718-549-3140

**E-mail:** registrar@veithsymposium.org or admin@veithsymposium.org
Full Registration  
☐ Practicing Physicians .......................................................... $1395  
☐ Practicing Physicians Combination Rate  
VEITHsymposium and AVIDsymposium ................................. $1895  
☐ US and Canadian Vascular Surgery Fellows  
In Training* .................................................................Complimentary  
☐ Non-U.S. Fellows  ☐ Nurse Practitioners  
☐ Physician Assistants .........................................................$695  
☐ Residents  ☐ Nurses  ☐ Technologists.................................$650  
☐ Allied Health Care Professionals .....................................$950  
*Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc.

Component Meetings (Tuition includes access to any Wednesday Only meeting.)  
☐ Wednesday Only - Endovenous Management of Varicose Veins ......................................................... $345  
☐ Wednesday Only - Hemodialysis Access...............................$345  
☐ Wednesday Only - WOUNDS ............................................. $345  
☐ Wednesday Only - WOUNDS (nurses only) ...................... $145  
☐ Wednesday Only - Emerging Management Options for Pulmonary Embolism ............... Included in all tuition categories  
☐ Wednesday Only - Management of Proximal Venous Obstruction.......................... Included in all tuition categories

First Name: _________________________________________________
Last Name (Surname) ____________________________________
Degree: __________________________
Specialty: __________________________________________________
Affiliation: __________________________________________________
Address Type: ☐ Home  ☐ Other
Address: __________________________________________________
City: __________________________ State/Province __________
Zip Code: __________________________ Country __________________
E-mail: ____________________________________________________
(A valid registrant’s e-mail address is required for confirmation and CME certificate.)
Phone: __________________________ Fax: _______________________

Payment Method
Check: Please make checks payable to the Cleveland Clinic Educational Foundation and mail to:
The Cleveland Clinic Educational Foundation  
Attn: VEITH 020892  
P.O. Box 931653  
Cleveland, OH 44193-1082

Name on Card: ____________________________________________
Credit Card Number: ____________________________________
Verification Code: _____________  Expiration Date: _____________
(Z-4 Digit Code on Credit Card)
Zip Code: __________________________ Country __________________
Signature: _______________________________________________
SAVE THE DATE

Wednesday – Sunday, November 20–24, 2013

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Daniel G. Clair, MD

Sponsored by

Cleveland Clinic

www.VEITHsymposium.org
Wednesday, November 14, 2012

- Hemodialysis Access
- Emerging Management Options for Pulmonary Embolism
- Management of Proximal Venous Obstruction
- Endovenous Management of Varicose Veins
- WOUNDS
- Multidisciplinary Acute Stroke Management

Again This Year
6th Annual Poster Session, Wednesday – Friday, November 14 – 16, 2012

Translation to Spanish, Portuguese, Russian and Mandarin Chinese will be available Thursday to Sunday.

www.veithsymposium.org